

Connecting via Winsock to Dialog

Logging in to Dialog

Trying 31060000009998...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

ENTER PASSWORD:

Welcome to DIALOG

Dialog level 05.27.00D

Last logoff: 09nov09 17:02:39

Logon file405 18nov09 16:53:59

*** ANNOUNCEMENTS ***

**** October 29, 2009 - Invoices to UK customers may be delayed by postal strike. Contact dialog.billing@dialog.com to request email delivery, or enter HELP INVOICE for details.****

*** FREE FILE OF THE MONTH: NOVEMBER

Foodline(R): SCIENCE (File 53)

Each month Dialog offers an opportunity to try out new or unfamiliar sources by offering \$100 of free searching (either DialUnits or connect time) in specified files. Output and Alerts charges are not included. For more details visit: <http://www.dialog.com/freefile/> and then take a moment to get familiar with another great Dialog resource.

NEW FILES

***File 106, Harvard Business Review Fulltext, Images

***File 558, Mergent China Private Company Database

***File 457, The Lancet(R)

FILES REMOVED

***File 59, Foodline: Legal

***File 614/814, Agence France-Presse English Wire

***File 615/815, Agence France-Presse Internat'l French Wire

>>>For the latest news about Dialog products, services, content<<<
>>>and events, please visit What's New from Dialog at <<<
>>><http://www.dialog.com/whatsnew/>. You can find news about <<<
>>>a specific database by entering HELP NEWS <file number>. <<<

* * *

SYSTEM:HOME

Cost is in DialUnits

Menu System II: D2 version 1.8.0 term=ASCII

*** DIALOG HOMEBASE(SM) Main Menu ***

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2003 Dialog, a Thomson business. All rights reserved.

/H = Help

/L = Logoff

/NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database

(e.g., B1 for ERIC).

? b 410

```
18nov09 16:53:59 User226352 Session D1191.1
      $0.00      0.267 DialUnits FileHomeBase
$0.00 Estimated cost FileHomeBase
$0.00 Estimated cost this search
$0.00 Estimated total session cost      0.267 DialUnits
```

File 410:The Chronolog 1991-2009/ Sep

(c) 2009 Dialog. All rights reserved.

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? b biochem

```
18nov09 16:54:02 User226352 Session D1191.2
      $0.00      0.117 DialUnits File410
$0.00 Estimated cost File410
$0.00 Estimated cost this search
$0.00 Estimated total session cost      0.384 DialUnits
```

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1926-2009/Nov W3

(c) 2009 The Thomson Corporation

File 6:NTIS 1964-2009/Nov W4
(c) 2009 NTIS, Intl Cpyrght All Rights Res

File 24:CSA Life Sciences Abstracts 1966-2009/Dec
(c) 2009 CSA.

File 34:SciSearch(R) Cited Ref Sci 1990-2009/Nov W2
(c) 2009 The Thomson Corp

File 40:Enviroline(R) 1975-2008/May
(c) 2008 Congressional Information Service

*File 40: This file is closed and will no longer update. For similar data, please search File 76-Environmental Sciences.

File 41:Pollution Abstracts 1966-2009/Dec
(c) 2009 CSA.

File 45:EMCare 2009/Nov W2
(c) 2009 Elsevier B.V.

File 50:CAB Abstracts 1972-2009/Nov W3
(c) 2009 CAB International

File 65:Inside Conferences 1993-2009/Nov 18
(c) 2009 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2009/Nov W2
(c) 2009 Elsevier B.V.

*File 71: The file has been reloaded. Accession numbers have changed.

File 72:EMBASE 1993-2009/Nov 18
(c) 2009 Elsevier B.V.

File 73:EMBASE 1974-2009/Nov 18
(c) 2009 Elsevier B.V.

File 76:Environmental Sciences 1966-2009/Dec
(c) 2009 CSA.

File 98:General Sci Abs 1984-2009/Nov
(c) 2009 The HW Wilson Co.

File 103:Energy SciTec 1974-2009/Oct B2
(c) 2009 Contains copyrighted material

*File 103: For access restrictions see Help Restrict.

File 136:BioEngineering Abstracts 1966-2007/Jan
(c) 2007 CSA.

*File 136: This file is closed.

File 143:Biol. & Agric. Index 1983-2009/Oct
(c) 2009 The HW Wilson Co

File 144:Pascal 1973-2009/Nov W3
(c) 2009 INIST/CNRS

File 154:MEDLINE(R) 1990-2009/Nov 17
(c) format only 2009 Dialog

File 155:MEDLINE(R) 1950-2009/Nov 17
(c) format only 2009 Dialog

File 156:ToxFile 1965-2009/Nov W3
(c) format only 2009 Dialog

File 162:Global Health 1983-2009/Nov W3
(c) 2009 CAB International

File 172:EMBASE Alert 2009/Nov 13
(c) 2009 Elsevier B.V.

*File 172: Due to technical issues on the supplier's side, there is no daily update 16 & 17 November.

File 305:Analytical Abstracts 1980-2009/Sep W4
(c) 2009 Royal Soc Chemistry
*File 305: Alert feature enhanced for multiple files, duplicate removal, customized scheduling. See HELP ALERT.
File 369:New Scientist 1994-2009/Nov W2
(c) 2009 Reed Business Information Ltd.
File 370:Science 1996-1999/Jul W3
(c) 1999 AAAS
*File 370: This file is closed (no updates). Use File 47 for more current information.
File 393:Beilstein Database - Abstracts 2008/Q2
(c) 2008 Beilstein GmbH
File 399:CA SEARCH(R) 1967-2009/UD=15121
(c) 2009 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 2006 The Thomson Corp

Set	Items	Description
---	-----	-----

```
? s serum (3n) sample (3n) ?teatment
>>>File 5 processing for ?TEATMENT stopped at ABSTRACT AESTHETIC
RESTORATIVE MATERIALS DIAGN
>>>File 6 processing for ?TEATMENT stopped at ARNEGARD
>>>File 24 processing for ?TEATMENT stopped at AMINO ACID SEQUENCE
PREDCITION
>>>File 34 processing for ?TEATMENT stopped at ACOPO
>>>File 40 processing for ?TEATMENT stopped at HOUSEPAINT
>>>File 41 processing for ?TEATMENT stopped at DARTERS
>>>File 45 processing for ?TEATMENT stopped at ATRIO-VENTRICULAR
ARRHYTHMIA
>>>File 50 processing for ?TEATMENT stopped at ALAAM
>>>File 65 processing for ?TEATMENT stopped at BERNADUS
>>>File 71 processing for ?TEATMENT stopped at ALCOHOL IN THE BLOOD
>>>File 72 processing for ?TEATMENT stopped at AGWAY
>>>File 73 processing for ?TEATMENT stopped at AEROPALYNOLOGIQUE
>>>File 76 processing for ?TEATMENT stopped at ANMV
>>>File 98 processing for ?TEATMENT stopped at CATSPER
>>>File 103 processing for ?TEATMENT stopped at ALLOW
>>>File 136 processing for ?TEATMENT stopped at DENTAL RESTORATIVE
FORMULATIONS
>>>File 143 processing for ?TEATMENT stopped at DIPOLYDORA HUELMA
>>>File 144 processing for ?TEATMENT stopped at ACIERA CR:15-20
NI:10-15 TI
C:0,1-0,23 H
>>>File 154 processing for ?TEATMENT stopped at ALLOCATABILITY
>>>File 155 processing for ?TEATMENT stopped at AG4L4
>>>File 156 processing for ?TEATMENT stopped at ANNEXIN A6 --ANALYSIS
--AN
```

```

>>>File 162 processing for ?TEATMENT stopped at AXIS
<-----User Break----->
u!
? s serum (3n) sample (3n) (treatment or pretreatment)
Processing
Processed 10 of 29 files ...
Processing
Processed 20 of 29 files ...
Completed processing all files
      4828858 SERUM
      3349774 SAMPLE
      18998347 TREATMENT
           276 PRETREATMENT
      S1      475 SERUM (3N) SAMPLE (3N) (TREATMENT OR PRETREATMENT)
? rd s1

>>>Duplicate detection is not supported for File 393.

>>>Records from unsupported files will be retained in the RD set.
      S2      146 RD S1 (unique items)
? s s2 not PY>2006
Processing
Processed 20 of 29 files ...
Completed processing all files
           146 S2
      22778661 PY>2006
      S3      117 S2 NOT PY>2006
? rd s3

>>>Duplicate detection is not supported for File 393.

>>>Records from unsupported files will be retained in the RD set.
      S4      117 RD S3 (unique items)
? s4 and acid
Processing
Processed 10 of 29 files ...
Processing
Processing
Processed 20 of 29 files ...
Processing
Completed processing all files
      24066014 4
      14799721 ACID
      S5 3720408 4 AND ACID
? s s4 and acid
           117 S4
      14799721 ACID
      S6      24 S4 AND ACID
? t s6/7/1-10
>>>Format 7 is not valid in file 143

6/7/1 (Item 1 from file: 5)

```

DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

16054360 BIOSIS NO.: 200100226199

Evaluation of detection methods for the reversed-phase HPLC
determination

of 3',4',5'-trimethoxyflavone in different phytopharmaceutical
products
and in human serum

AUTHOR: Huck Christian W (Reprint); Bonn Guenther K

AUTHOR ADDRESS: Institute of Analytical Chemistry, and Radiochemistry,
Leopold-Franzens University, Innrain 52a, 6020, Innsbruck, Austria**
Austria

JOURNAL: Phytochemical Analysis 12 (2): p104-109 March-April, 2001

MEDIUM: print

ISSN: 0958-0344

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Quantitative determination of the major compound,
3',4',5'-trimethoxyflavone (1), in plant extracts, in tablets of
Flos and
of Radix Primulae veris and in human serum has been accomplished
using

reversed-phase HPLC with UV, fluorescence and mass spectrometric
(MS)

detection. Compared to UV detection, fluorescence detection showed
greater selectivity, was 10-fold more sensitive and allowed the
determination of 1 in human serum after sample pre-
treatment by solid-phase extraction. MS detection of 1 using
electrospray ionisation (ESI) interface could be improved by
substituting

trifluoroacetic acid with the more polar and less conductive
additive acetic acid, giving rise to a 230-fold improvement in
analyte detectability at the cost of an increase of only 45% in the
peak

width of the eluting peak at its half height. Further optimisation
of the

acetic acid concentration showed the highest signal intensity at
1.25% for HPLC-atmospheric pressure chemical ionisation (APCI)-MS
and at

0.75% for HPLC-ESI-MS. The optimised MS method proved to be
extremely

selective, 50 times more sensitive than UV detection and 5 times
more

sensitive than fluorescence detection. Furthermore, fragment-ion
spectra

produced by collision induced dissociation-MS have been used as
"fingerprints" for identifying compounds in the highly complex
mixtures

examine.

6/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

09760076 BIOSIS NO.: 198988075191
ASSESSMENT OF AN RIBOSOMAL DNA PROBE FILTER HYBRIDIZATION ASSAY FOR
THE

DETECTION OF RIFT VALLEY FEVER VIRUS RNA IN HUMAN SERUM SAMPLES
FROM THE

MAURITANIAN EPIDEMIC

AUTHOR: KNAUERT F K (Reprint); MEEGAN J M; JOUAN A; KSIAZEK T G; LE
GUENNO

B; SARTHOU J L; PETERS C J; DIGOUTTE J P

AUTHOR ADDRESS: DISEASE ASSESSMENT DIV, UNITED STATES ARMY MED RES
INST

INFECTIOUS DISEASES, FT DETRICK, FREDERICK, MD 21701-5011, USA**USA
JOURNAL: Research in Virology 140 (1): p47-58 1989

ISSN: 0923-2516

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: The Rift Valley fever virus (RVFV) epidemic that occurred in
southern Mauritania during the 1987 rainy season provided a unique
opportunity to test and evaluate a recently developed,
M-segment-specific, nucleic acid filter hybridization assay on a
large collection of infected human serum samples. It afforded the
opportunity to compare the procedure with two other methods for
detecting

virus: virus isolation and antigen detection by ELISA. The filter
hybridization procedure employed a
polyethylene-glycol-precipitation and
proteinase-K-digestion sample treatment step developed
specifically for preparing serum samples for hybridization. The
procedure was less sensitive for detecting RVFV in the Mauritanian
human

viremic samples than in sera from experimentally infected monkeys
used to

evaluate this procedure. It was also less sensitive than an antigen
detection procedure used to test the Mauritanian samples. However,

we

were able to detect virus RNA in a significant proportion of the
virus-isolation-positive samples. Advances in sample preparation,
labelling and detection procedures, and hybridization methods will
improve the sensitivity, precision and ease of use of this assay and
increase its value as a diagnostic tool.

6/7/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

09270216 BIOSIS NO.: 198886110137
DETERMINATION OF COPPER AND ZINC IN SERUM AND WHOLE BLOOD BY ION
CHROMATOGRAPHY
AUTHOR: ONG C N (Reprint); ONG H Y; CHUA L H
AUTHOR ADDRESS: DEP COMMUNITY MED, NATL UNIV SINGAPORE, NATL UNIV
HOSP,
KENT RIDGE, SINGAPORE 0511**SINGAPORE
JOURNAL: Analytical Biochemistry 173 (1): p64-69 1988
ISSN: 0003-2697
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: An ion chromatography (IC) method for the determination of
copper
and zinc in serum and whole blood is described. The sample
treatment consists of diluting (2:3 for serum and 1:3 for
whole blood) with 50% trichloroacetic acid, centrifuging, and
dispensing the liquid directly into the chromatograph. The standard
additions technique is used to establish the calibration. The close
agreement between IC and spectrophotometric data on copper and zinc
in
serum and whole blood suggests that ion chromatography may be
applied to
complex biological matrices with minimal sample preparation.

6/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

08208677 BIOSIS NO.: 198682055064
A METHOD FOR THE ENZYMATIC IDENTIFICATION OF A URIC-ACID PEAK IN A
LIQUID CHROMATOGRAM OF RAT SERUM MONITORED BY AN ELECTROCHEMICAL
DETECTOR
AUTHOR: IWAMOTO T (Reprint); TOMIZAWA N; YOSHIURA M; KURIHARA S;
IRIYAMA K
AUTHOR ADDRESS: DIV BIOCHEM, CENT RES LAB, JIKEI UNIV SCH MED, 3-25-8,
NISH-SHINBASHI, MINATO-KU, TOKYO 105, JPN**JAPAN
JOURNAL: Jikeikai Medical Journal 33 (1): p11-16 1986
ISSN: 0021-6968
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Peak purity of uric acid in a liquid chromatogram of rat
serum has been examined by the enzymatic treatment of the body
fluid with
uricase (EC 1.7.3.3). The enzyme catalyzes the conversion of uric

acid to allantoin. Eluate from a column was amperometrically monitored by aid of an electrochemical detector. Uric acid can be electrochemically oxidized under the chromatographic conditions used in this study, whereas allantoin cannot. The complete disappearance of a uric acid peak in a liquid chromatogram after the uricase treatment of rat serum indicates that the uric acid peak does not contain any other electroactive components. By using the enzymatic peak identification method, we have actually observed the complete disappearance of the uric acid peak in a liquid chromatogram of rat serum after the enzymatic treatment of the sample.

6/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

06331007 BIOSIS NO.: 198172064958
LIQUID CHROMATOGRAPHIC ASSAY FOR METRONIDAZOLE AND TINIDAZOLE PHARMACO
KINETIC AND METABOLIC STUDIES IN HUMAN SUBJECTS
AUTHOR: NILSSON-EHLE I (Reprint); URSING B; NILSSON-EHLE P
AUTHOR ADDRESS: DEP OF INFECTIOUS DISEASES, UNIV OF LUND, S-221 85
LUND,
SWEDEN**SWEDEN
JOURNAL: Antimicrobial Agents and Chemotherapy 19 (5): p754-760 1981
ISSN: 0066-4804
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Methods were developed for measuring metronidazole, its 2 major metabolites and tinidazole in serum and urine. After treatment of each sample with an equal volume of 5% perchloric acid, the drugs were separated by reverse-phase high-pressure liquid chromatography (retention times, 6-18 min). Quantitation was based on spectrometry at 320 nm. These assays were sensitive, rapid and specific and recoveries from biological samples were quantitative. Metronidazole and tinidazole were given as rapid i.v. infusions to 4 healthy human volunteers. The biological half-lives of these 2 compounds were 5.4 and 11.1 h, respectively. The hydroxy metabolite of metronidazole appeared quickly in serum and was eliminated at a slow rate. The acetic acid metabolite of metronidazole was detected in serum at very low levels and only for a limited time. No metabolic products of tinidazole were found in serum samples. In urine, 43.7% of the administered dose of metronidazole was recovered over a

period of 24 h (24.1% of the dose as the hydroxy metabolite, 12.0% as the acetic acid metabolite and 7.6% as unchanged drug). Only 18.4% of the infused dose of tinidazole was eliminated in urine over a period of 72 h and no metabolic products were detected.

6/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

06287757 BIOSIS NO.: 198172021708
ISOZYMES OF RNASE IN HUMAN SERUM AND URINE 1. METHODOLOGY AND A SURVEY OF A CONTROL POPULATION
AUTHOR: THOMAS J M (Reprint); HODES M E
AUTHOR ADDRESS: DEP MED GENET, INDIANA UNIV SCH MED, INDIANAPOLIS, INDIANA 46223, USA**USA
JOURNAL: Clinica Chimica Acta 111 (2-3): p185-198 1981
ISSN: 0009-8981
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Methods are presented for the electrophoretic analysis of RNase enzymes in human serum and urine. Protocols for sample treatment, electrophoresis, and the RNase zymogram technique are described. With the application of these methods, RNase from serum and urine was separated into components differing on the basis of charge (charge isomers of isozymes), but not differing with respect to hydrolyzable sialic acid residues. Preliminary characterization of the electrophoretically separated components showed that some of the RNase species have different properties (pH optima and substrate preference). The major urine RNase isozymes appeared to be distinct from the major serum RNase isozymes. A survey of a control population indicated that the major serum and urine RNase enzymes are not genetically polymorphic.

6/7/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

05659775 BIOSIS NO.: 197967048770
ISO ENZYMES OF HUMAN PROSTATE ACID PHOSPHATASE
AUTHOR: CHU T M (Reprint); WANG M C; MERRIN C; VALENZUELLA L; MURPHY G P

AUTHOR ADDRESS: ROSWELL PARK MEML INST, 666 ELM ST, BUFFALO, NY
14263, USA

**USA

JOURNAL: Oncology (Basel) 35 (5): p198-200 1978

ISSN: 0030-2414

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: The isoenzymes of human prostatic acid phosphatase were studied by an isoelectric focusing technique. Purified acid phosphatase from malignant prostates contained 8 isoenzymes with pI 4.4-5.3. The sera from patients with prostate cancer had similar acid phosphatase isoenzyme patterns at pI 4.0-5.5; as the serum enzyme activities increased the pI of isoenzymes shifted to more acidic pH. These isoenzyme patterns of sera from patients with prostate cancer were different from those of patients with Gaucher's disease or from acid phosphatase of human erythrocytes, both of which exhibited only 1 enzyme band around pI [isoelectric point] 5.0 and 6.0, respectively. Treatment of serum sample of prostate cancer with neuraminidase did not result in a single enzyme band but altered the pI of isoenzymes, which shifted to a higher pH region. The significance of acid phosphatase activities and its isoenzyme patterns in prostate cancer merits further investigation.

6/7/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0001810747 BIOSIS NO.: 19674800094753
Effect of hydrogen peroxide on whey protein nitrogen value of heated
skimmilk

AUTHOR: FISH NANCY L; MICKELSEN R
AUTHOR ADDRESS: Kans. State Univ., Manhattan, Kans., USA
JOURNAL: J DAIRY SCI 50 ((7)): p1045-1048 1967 1967
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Unspecified

ABSTRACT: The effect on the whey protein nitrogen value of skimmilk treated with different concentrations of hydrogen peroxide in the skimmilk 10 min. before it was heated at 85 degrees C for 30 min. was determined. Hydrogen peroxide decreased denaturation of skimmilk. Disc electrophoresis patterns were compared for normal, heated, hydrogen peroxide-heated and hydrogen peroxide-heated-catalase-treated samples of

[alpha]-lactalbumin, bovine serum albumin (BSA),
[beta]-lactoglobulin and
acid whey. The [alpha]-lactalbumin band was lighter in the hydrogen
peroxide-treated sample than in the normal or heated sample. Bovine
serum albumin was denatured by heat treatment. Hydrogen
peroxide prevented total denaturation of BSA. [beta]-lactoglobulin
was
denatured by heat treatment and extensively modified by hydrogen
peroxide. The electrophoretic pattern of hydrogen peroxide-heated
acid whey had a darker band in the position normally occupied by
[alpha]-lactalbumin. Hydrogen peroxide modified
[beta]-lactoglobulin to
form a band in the same position. A component not found in hydrogen
peroxide-heated acid whey was in the electrophoretic pattern of
acid whey from hydrogen peroxide-heated skimmilk, possibly from a
reaction of hydrogen peroxide with a casein protein to form a
product not
precipitated with the casein. ABSTRACT AUTHORS: Authors

6/7/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0001491306 BIOSIS NO.: 19654600005397
Observations on the estimation of serum cholesterol using the ferric
chloride reaction
AUTHOR: NAIR SHANTHA KUMARI; VENKATARAMAN A
AUTHOR ADDRESS: Haffkine Inst., Parel, Bombay, India
JOURNAL: IND J MED RES 52 ((4)): p381-391 1964 1964
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Unspecified

ABSTRACT: The direct treatment of the serum sample with
the ferric chloride Reagent (Rosenthal's) results in extra chromogen
which is quantitatively accounted for by the color produced by the
precipitated proteins with the same reagent. Once the proteins are
removed, the traces of aldehydic impurities in glacial acetic acid
do not affect this reaction with cholesterol. Only tryptophane
either as
free amino acid or bound in proteins interferes with this reaction.
Laboratory grade absolute alcohol is better than glacial acetic
acid for precipitating the proteins and as solvent for the color
development. Only micro quantities of blood samples are required
and the
whole procedure can be finished in 30 minutes. ABSTRACT AUTHORS: S.
K.
Nair

6/7/10 (Item 10 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0001003256 BIOSIS NO.: 19593400000708

A simple method for determination of inorganic blood iodine
ORIGINAL LANGUAGE TITLE: Eine einfache Methode zur Bestimmung des
anorganischen Blutjodes

AUTHOR: KLEIN ERICH

AUTHOR ADDRESS: Inneren Klin Krankenhauses, Stuttgart-Bad Canstatt,
Germany

JOURNAL: BIOCHEM ZEITSCHR 326 ((1)): p9-13 1954 1954

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: Unspecified

ABSTRACT: Inorganic serum iodine is determined as iodide in the
supernate
after trichloroacetic acid treatment of the serum
sample. The method described is a modification of the cerous
sulfate-arsenite reaction for determining iodide. The method makes
possible determination of inorganic serum iodine as distinguished
from
organic iodine contained in compounds removed from solution by
protein-precipitating agents. A comparison of results of analyses
of sera
of 20 normal and 20 hyperthyroid subjects showed that the sera of
the
hyperthyroid patients had an average of about twice as much
inorganic
serum iodine as did the normal subjects. ABSTRACT AUTHORS: MDS
? ds

Set	Items	Description
S1	475	SERUM (3N) SAMPLE (3N) (TREATMENT OR PRETREATMENT)
S2	146	RD S1 (unique items)
S3	117	S2 NOT PY>2006
S4	117	RD S3 (unique items)
S5	3720408	4 AND ACID
S6	24	S4 AND ACID
? s s6 and (immunoassay or antibody)		
	24	S6
	475337	IMMUNOASSAY
	3552141	ANTIBODY
	S7	3 S6 AND (IMMUNOASSAY OR ANTIBODY)

? t s7/7/all

>>>Format 7 is not valid in file 143

7/7/1 (Item 1 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2009 The Thomson Corp. All rts. reserv.

16170774 Genuine Article#: 142DL Number of References: 51

Title: Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass

spectrometric detection

Author: Hendrickson H (REPRINT) ; Laurenzana E; Owens SM

Corporate Source: Univ Arkansas Med Sci, Coll Pharm, Dept Pharmaceut Sci, 4301 W Markham St 522-3/Little Rock//AR/72205 (REPRINT); Univ Arkansas Med Sci, Coll Pharm, Dept Pharmaceut Sci, Little

Rock//AR/72205;

Coll Med, Dept Pharmacol & Toxicol, Little Rock//AR/

Journal: AAPS JOURNAL, 2006, V8, N4, PE709-E717

ISSN: 1550-7416 Publication Date: 20060000

Publisher: AMER ASSOC PHARMACEUTICAL SCIENTISTS, 2107 WILSON BLVD, STE 700,

ARLINGTON, VA 22201-3042 USA

Language: English Document Type: ARTICLE

Abstract: High-throughput liquid chromatography with tandem mass spectrometric detection (LC-MS/MS) methodology for the determination of

methamphetamine (METH), amphetamine (AMP),

4-hydroxymethamphetamine

(4-OH-METH), and 4-hydroxyamphetamine (4-OH-AMP) was developed and validated using simple trichloroacetic acid sample treatment. The method was validated in rat serum, brain, and testis. Lower limits-of-quantitation (LOQ) for METH and AMP

were 1

ng center dot mL(-1) using positive ion electrospray tandem mass spectrometry (MS/MS). The accuracy of the method was within 25%

of the

actual values over a wide range of analyte concentrations. The within-assay precision was better than 12% (coefficient of variation).

The method was linear over a wide dynamic range (0.3-1000 ng center dot

mL(-1)). Quantitation was possible in all 3 matrices using only serum

standards because of minimal matrix-associated ion effects or the use

of an internal standard. Finally, the LC-MS/MS method was used to determine serum, brain, and testis METH and AMP concentrations during a

subcutaneous infusion (5.6 mg kg(-1) day(-1)) of METH in rats. Concentrations of 4-OH-AMP and 4-OH-METH were below the LOQ in experimental samples. The bias introduced by using serum

calibrators

for the determination of METH and AMP concentrations in testis and brain was less than 8% and insignificant relative to the

interanimal

variability.

DIALOG(R)File 305:Analytical Abstracts
(c) 2009 Royal Soc Chemistry. All rts. reserv.

141424 AA Accession Number: 50-02-D-00246 DOC. TYPE: Journal
Sandwich enzyme immunoassay of total insulin in serum containing
insulin antibodies.

AUTHOR: Tominaga, M.; Honda, M.; Itoh, Y.; Mokuda, O.; Ikeda, T.;
Mashiba,
H.

CORPORATE SOURCE: First Dept. Internal Med., Tottori Univ. Sch. Med.,
Yonago 683, Japan

JOURNAL: Clin. Chim. Acta, Volume: 169, Issue: 1, Page(s): 141

CODEN: CCATAR ISSN: 0009-8981

PUBLICATION DATE: Oct 1987 (871000) LANGUAGE: English

ABSTRACT: In the sandwich enzyme immunoassay described by Kohno et
al. (Ibid., 1987, 163, 105) for total insulin (I)
determination in

serum containing endogenous antibodies to I, it was considered
that the
endogenous antibodies were inactivated by acid pre-treatment of
the sample. I was determined with the insulin EIA kit (Mochida,
Tokyo,
Japan); dilution of the sample serum without acid
treatment was adequate to avoid interference from the endogenous
antibodies.

7/7/3 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

139336482 CA: 139(22)336482s PATENT

Diagnosis and treatment of proliferative abnormalities associated
with

overexpression of human transketolase like-1 gene

INVENTOR(AUTHOR): Coy, Johannes

LOCATION: Germany,

PATENT: European Pat. Appl. ; EP 1354961 A1 DATE: 20031022

APPLICATION: EP 20028831 (20020419)

PAGES: 28 pp. CODEN: EPXXDW LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12Q-001/68A

DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI;
LU; NL;

SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR

SECTION:

CA214001 Mammalian Pathological Biochemistry

CA201XXX Pharmacology

CA203XXX Biochemical Genetics

IDENTIFIERS: diagnosis treatment proliferative abnormality human
transketolase overexpression, cancer diagnosis therapy human
transketolase overexpression

DESCRIPTORS:

Cell proliferation...
 abnormal; diagnosis and treatment of proliferative abnormalities
 associated with overexpression of human transketolase like-1 gene

Lung,neoplasm...
 adenocarcinoma, diagnosis and treatment of; diagnosis and
treatment of
 proliferative abnormalities associated with overexpression of
human
 transketolase like-1 gene

Antitumor agents...
 antithiamine; diagnosis and treatment of proliferative
abnormalities
 associated with overexpression of human transketolase like-1 gene

Luminescent substances...
 bioluminescent, probe for diagnosis labeled with; diagnosis and
treatment of proliferative abnormalities associated with
overexpression of
 human transketolase like-1 gene

Diagnosis...
 cancer; diagnosis and treatment of proliferative abnormalities
associated
 with overexpression of human transketolase like-1 gene

Stomach,neoplasm...
 carcinoma, diagnosis and treatment of; diagnosis and treatment of
proliferative abnormalities associated with overexpression of
human
 transketolase like-1 gene

Intestine,neoplasm...
 colon, carcinoma, diagnosis and treatment of; diagnosis and
treatment
 of proliferative abnormalities associated with overexpression of
human
 transketolase like-1 gene

Intestine,neoplasm...
 colon, diagnosis and treatment of; diagnosis and treatment of
proliferative abnormalities associated with overexpression of
human
 transketolase like-1 gene

Antibodies... Antitumor agents... Blood analysis... Drug screening...
Epitopes... Human... Immunotherapy... Peptidomimetics...
Primers(nucleic
acid)... Probes(nucleic acid)... Urine analysis...
 diagnosis and treatment of proliferative abnormalities associated
with
 overexpression of human transketolase like-1 gene

Lung,neoplasm... Neoplasm... Pancreas,neoplasm... Stomach,neoplasm...
 diagnosis and treatment of; diagnosis and treatment of
proliferative
 abnormalities associated with overexpression of human
transketolase like-1
gene

NASBA(nucleic acid sequence-based amplification)... Nucleic acid amplification(method)... Nucleic acid hybridization... PCR(polymerase chain reaction)... Test kits...
 for diagnosis; diagnosis and treatment of proliferative abnormalities
 associated with overexpression of human transketolase like-1 gene
Antisense nucleic acids...
 for transketolase like-1 gene; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Ribozymes...
 for transketolase like-1; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Immunoassay...
 immunocytochem., for diagnosis; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Diagnosis...
 immunodiagnosis; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Nucleic acid hybridization...
 in situ, for diagnosis; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Genetic methods...
 LCR (ligase chain reaction), for diagnosis; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Chelates... Chemiluminescent substances... Enzymes,biological studies...
Fluorescent substances... Radionuclides...
 probe for diagnosis labeled with; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
PCR(polymerase chain reaction)...
 RT-PCR (reverse transcription-PCR), for diagnosis; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Animal cell... Animal tissue... Bile... Blood serum... Body fluid... Feces

... Semen...
 sample for diagnosis from; diagnosis and treatment of
 proliferative
 abnormalities associated with overexpression of human
 transketolase like-1
 gene
 Nucleic acids... Peptides,biological studies...
 sample for diagnosis; diagnosis and treatment of proliferative
 abnormalities associated with overexpression of human
 transketolase like-1
 gene
 Gene,animal...
 TKT-L1; diagnosis and treatment of proliferative abnormalities
 associated
 with overexpression of human transketolase like-1 gene
 Immunization...
 vaccination; diagnosis and treatment of proliferative
 abnormalities
 associated with overexpression of human transketolase like-1 gene
 CAS REGISTRY NUMBERS:
 9014-48-6 -like; diagnosis and treatment of proliferative
 abnormalities
 associated with overexpression of human transketolase like-1 gene
 174944-79-7 diagnosis and treatment of proliferative abnormalities
 associated
 with overexpression of human transketolase like-1 gene
 615290-51-2 615290-52-3 615290-53-4 615290-54-5 primer; diagnosis
 and
 treatment of proliferative abnormalities associated with
 overexpression of
 human transketolase like-1 gene
 615290-50-1 probe; diagnosis and treatment of proliferative
 abnormalities
 associated with overexpression of human transketolase like-1 gene
 ? ds

Set	Items	Description
S1	475	SERUM (3N) SAMPLE (3N) (TREATMENT OR PRETREATMENT)
S2	146	RD S1 (unique items)
S3	117	S2 NOT PY>2006
S4	117	RD S3 (unique items)
S5	3720408	4 AND ACID
S6	24	S4 AND ACID
S7	3	S6 AND (IMMUNOASSAY OR ANTIBODY)
? s adiponectin		
S8	55814	ADIPONECTIN
? s s8 and (assay or immunoassy)		
	55814	S8
	3689188	ASSAY
	196	IMMUNOASSY
S9	3402	S8 AND (ASSAY OR IMMUNOASSY)
? s s9 not PY>2006		

3402 S9
22778661 PY>2006
S10 1185 S9 NOT PY>2006
? rd s10

>>>Duplicate detection is not supported for File 393.

>>>Records from unsupported files will be retained in the RD set.

S11 352 RD S10 (unique items)

? t s11/7/1-10

>>>Format 7 is not valid in file 143

11/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019986882 BIOSIS NO.: 200800033821

Adiponectin in early and chronic rheumatoid arthritis and
osteoarthritis

AUTHOR: Laurberg T (Reprint); Ellingsen T; Frystyk J; Hansen I;
Jorgensen A

; Tarp U; Hetland M; Horslev-Petersen K; Homung N; Poulsen J;
Flyvbjerg A

; Stengaard-Pedersen K

AUTHOR ADDRESS: Hvidovre Univ Hosp, Clin Rheumatol, DK-2650 Hvidovre,
Denmark**Denmark

JOURNAL: Annals of the Rheumatic Diseases 65 (Suppl. 2): p307-308
JUL 2006

2006

CONFERENCE/MEETING: Annual European Congress of Rheumatology (EULAR
2006)

Amsterdam, NETHERLANDS June 21 -24, 2006; 20060621

ISSN: 0003-4967

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Citation

LANGUAGE: English

11/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019698701 BIOSIS NO.: 200700358442

Globular adiponectin augments from pancreatic islet beta cells at
insulin secretion high glucose concentrations

AUTHOR: Gu Weiqiong; Li Xiaoying; Liu Changqin; Yang Jun; Ye Lei; Tang
Jingfen; Gu Yuanjun; Yang Yisheng; Hong Jie; Zhang Yifei; Chen
Mingdao;

Ning Guang (Reprint)

AUTHOR ADDRESS: Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept
Endocrinol and Metab, Shanghai Clin Ctr Endocrine and Metab Dis,
Ruijin

2nd Rd, Shanghai 200025, Peoples R China**Peoples R China
AUTHOR E-MAIL ADDRESS: guangning@medmail.com.cn
JOURNAL: Endocrine 30 (2): p217-221 OCT 2006 2006
ISSN: 0969-711X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Adiponectin plays an important role in improving insulin resistance and preventing atherosclerosis. However it has been rarely reported that adiponectin influences insulin secretion because its receptor was identified in human islet P cells. In order to investigate the direct effect of adiponectin on pancreatic islet 0 cells, we performed an insulin secretion test in purified rat islets, which were incubated with adiponectin (100 ng/mL) at low (3.3 mM) and high (16.7 mM) glucose concentrations. Furthermore, cell lysates were extracted from the adiponectin-treated islets for p-AMPK alpha assay. RTPCR and immunohistochemical examination showed both adiponectin receptor 1 (AdipoR1) and receptor 2 (AdipoR2) were expressed in islet cells and AdipoR1 was predominantly expressed. Insulin secretion was significantly increased in the presence of adiponectin for 6 h at high glucose concentration. Meanwhile, the levels of phosphorylated AMPK increased with adiponectin treatment at high glucose concentrations. It is concluded that adiponectin augments insulin secretion from pancreatic islet P cells at high glucose concentration through AMPK activation.

11/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019678755 BIOSIS NO.: 200700338496
Effects of recombinant adenovirus encoding human apM1 gene on proliferation and nitric oxide synthase activity in human umbilical vein endothelial cells
AUTHOR: Li Bing-rong; Zheng Dan; Deng Hua-cong (Reprint); Liu Jin-bo; Lan

Li-zhen; Zheng Hong-ting
AUTHOR ADDRESS: Chongqing Univ Med Sci, Affiliated Hosp 1, Dept Endocrinol,

Chongqing 400016, Peoples R China**Peoples R China
AUTHOR E-MAIL ADDRESS: denghuacong@yahoo.com.cn
JOURNAL: Zhonghua Xinxueguanbing Zazhi 34 (12): p1122-1125 DEC 2006 2006

ISSN: 0253-3758
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Chinese

ABSTRACT: Objective To evaluate the effects of recombinant adenovirus encoding human apM1 gene on proliferation and nitric oxide synthase (NOS) activity in human umbilical vein endothelial cells HUVECs).

Methods

Protein expression of apM1 in cell culture supernatant of HUVECs transfected with human Ad-apM1 was detected by double antibody sandwich

ELISA. The effect of human adiponectin on cell proliferation was assessed by MTT assay. The total NOS and iNOS expressions were measured by chromatometry. Results Human adiponectin protein level and total NOS and eNOS expressions were significant increased and iNOS

expression significantly reduced in culture supernatant of HUVECs infected with Ad-apM1 compared to that in control HUVECs. The recombinant

adenovirus had no influence on HUVECs growth as determined by WITT assay. Conclusions Human Ad-apM1 can be effectively expressed in HUVECs and do not influence HUVECs growth. Increased total NOS and eNOS

expressions and decreased iNOS expression in HUVECs transfected with Ad-apM1 gene suggest a potential role of Ad-apM1 gene transfer for the prevention and treatment of arteriosclerosis.

11/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019605892 BIOSIS NO.: 200700265633
Elevated plasma HDL-cholesterol levels by CETP gene polymorphism and atherosclerosis; The J-SHIPP study
AUTHOR: Haiyan Guo (Reprint); Tabara Yasuharu; Kawamoto Ryuichi; Tachibana-Iimori Rieko; Yamamoto Miyuki; Nakura Jun; Miki Tetsuro; Kohara

Katsuhiko
AUTHOR ADDRESS: Ehime Univ, Sch Med, Dept Geriatr Med, Matsuyama, Ehime

790, Japan**Japan
AUTHOR E-MAIL ADDRESS: tabara@m.ehime-u.ac.jp
JOURNAL: Journal of Hypertension 24 (Suppl. 6): p279 DEC 2006 2006
CONFERENCE/MEETING: 21st Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension Fukuoka, JAPAN October 15 -19, 2006;

20061015
SPONSOR: Int Soc Hypertens
Japanese Soc Hypertens
ISSN: 0263-6352
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Citation
LANGUAGE: English

11/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019598281 BIOSIS NO.: 200700258022
Adiponectin produced by lymphocytes inhibits granulopoiesis.
AUTHOR: Crawford Lisa J (Reprint); Peake Roy W; Price Susan; Morris
Treen C

; Irvine Alexandra E
AUTHOR ADDRESS: Queens Univ Belfast, Belfast, Antrim, UK**UK
JOURNAL: Blood 108 (11, Part 1): p374A NOV 16 2006 2006
CONFERENCE/MEETING: 48th Annual Meeting of the
American-Society-of-Hematology Orlando, FL, USA December 09 -12,
2006;

20061209
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Previous studies by our group have shown that normal
unstimulated

lymphocytes produce a protein which inhibits colony formation
of granulopoietic progenitors, but has no effect on erythroid
progenitors.

Therefore, this inhibitor was initially designated GIA
(granulopoietic

inhibitory activity). GIA was identified as a glycoprotein of
approximately 30 kDa, with a pI of 7.9 - 8.4. Furthermore, we
demonstrated

that this inhibitor may have physiological significance in that its
production is altered in patients with neutropenia. GIA has proved
difficult to characterise to date since it is produced in
relatively low

amounts although it has a high specific biological activity.

Adiponectin is an adipokine reported to share many of the
inhibitory characteristics of GIA and has been demonstrated to act
as a

negative regulator of hematopoiesis and immune response. This study
aimed

to determine whether GIA is adiponectin or if it represents an
adiponectin-like molecule. Lymphocyte conditioned medium (LCM) from

lymphocytes cultured at 1×10^6 cells/ml in HL- I minimal medium was used as a source of GIA. Inclusion of LCM as 10% of the top layer of agar in a myeloid colony assay inhibited growth of CFU-GM by 52.11% (n=3), confirming the presence of the inhibitory activity. RNA and protein from lymphocytes and LCM harvested over a 7 day culture period were subsequently investigated for adiponectin expression. Western blot analysis demonstrated a distinct banding pattern in days 3-7 LCM corresponding to monomers, dimers, trimers and greater. This is consistent with adiponectin which circulates as a multimer of trimers. Characterisation of GIA at the transcript level confirmed that GIA is in fact adiponectin. The N-terminal collagenous domain, C terminal globular domain and full length adiponectin were amplified by RT-PCR analysis. Adiponectin is thought to be secreted exclusively from adipocytes and much of our current knowledge of this molecule relates to its metabolic functions. Our study provides evidence that adiponectin is also produced by lymphocytes and may play a role in the pathogenesis of neutropenia.

11/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019511228 BIOSIS NO.: 200700170969
Association of hypo adiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses
AUTHOR: Hashimoto Naotake (Reprint); Kanda Junji; Nakamura Tomonori; Horie
Atsuya; Kurosawa Hiroko; Hashimoto Toru; Sato Kazutoshi; Kushida Syunichi
; Suzuki Masaru; Yano Shingo; Iwai Rie; Takahashi Hidenori; Yoshida Shouji
AUTHOR ADDRESS: Asahi Gen Hosp, Dept Diabet and Metab Dis and Internal Med,
Chiba 2892511, Japan**Japan
AUTHOR E-MAIL ADDRESS: naohasi@hospital.asahi.chiba.jp
JOURNAL: Metabolism Clinical and Experimental 55 (12): p1653-1657
DEC 2006
2006
ISSN: 0026-0495
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Adiponectin influences insulin sensitivity and lipid

oxidation. Because low plasma adiponectin concentrations are suspected to promote atherosclerosis, we retrospectively assessed relationships of plasma adiponectin concentration to characteristics of coronary heart disease (CHD). Japanese men undergoing coronary angiography for CHD (n = 139) were grouped according to serum adiponectin concentration by enzyme-linked immunosorbent assay (low, < 4.0; medium, 4.0-8; high, > 8.0 μ g/mL). Numbers of coronary arteries with at least 50% stenosis were determined. Serum adiponectin concentration correlated positively with age at onset of CHD (r = 0.285, P = .003). Age at CHD onset in the low-adiponectin group was younger than in the medium or high groups. Adiponectin was protective against CHD onset at ages younger than 58 years (relative risk, 0.778; P = .0047). Significantly more arteries were affected in low-adiponectin patients than in the medium or high group (each P < .01). Adiponectin concentration correlated positively with high-density lipoprotein cholesterol concentration and negatively with triglyceride concentration. Only in diabetic patients did serum adiponectin concentration correlate negatively with body mass index. Low plasma adiponectin concentrations were associated with early CHD onset and multiple atherosclerotic lesions in coronary arteries. Thus, adiponectin concentrations may influence risk of CHD and might serve as one of the screening tests facilitating early intervention. (c) 2006 Elsevier Inc. All rights reserved.

11/7/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019511227 BIOSIS NO.: 200700170968
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy
AUTHOR: Matsumoto Sachiko; Takebayashi Kohzo (Reprint); Aso Yoshimasa
AUTHOR ADDRESS: Dokkyo Univ, Dept Internal Med, Koshigaya 3438555, Japan**
Japan
AUTHOR E-MAIL ADDRESS: takeb@gmail.plala.or.jp
JOURNAL: Metabolism Clinical and Experimental 55 (12): p1645-1652
DEC 2006
2006
ISSN: 0026-0495
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Angiotensin II can influence adipocytokine levels in adipose tissue, but the association between aldosterone, which mediates the effect of angiotensin II, and adipocytokines has yet to be fully elucidated. This study was designed to investigate the effect of spironolactone, a representative aldosterone blocker, on adipocytokines such as adiponectin, visfatin, plasminogen activator inhibitor (PAI)-I and tumor necrosis factor alpha in patients with type 2 diabetic nephropathy: the study included 33 patients, 22 of whom were randomly assigned to the spironolactone (50 mg/d) group and 11 to the amlodipine (2.5 mg/d) group. Data were collected at baseline and after 3 months of treatment and compared with baseline data for 25 age-matched healthy subjects. A significant decrease in plasminogen activator inhibitor 1 in the spironolactone group was observed (22.6 ± 13.4 to 19.2 ± 11.3 ng/mL, $P = .0323$), but this did not occur in the amlodipine group. Adiponectin and visfatin levels did not change in the spironolactone and amlodipine groups, but significant increases in these adipocytokines were found in a subgroup of patients in the spironolactone group with glycated hemoglobin A(1c) (HbA(1c)) 8.0% or greater (11.8 ± 6.4 to 13.3 ± 7.4 μ g/mL, $P = .0344$; and 1.39 ± 0.92 to 2.26 ± 0.76 ng/mL, $P = .0397$, respectively). The tumor necrosis factor alpha level at baseline exceeded the lower detection limit of the assay in only 6 patients in the spironolactone group, and no change occurred in these patients. Moreover, neither spironolactone nor amlodipine therapy caused a change in high-sensitivity C-reactive protein or soluble CD40 ligand, but a significant decrease in the level of brain natriuretic peptide was found in the spironolactone group only. Furthermore, significant increases of HbA(1c), creatinine, potassium, and aldosterone levels and plasma renin activity, and a decrease in urinary albumin excretion were also observed only in the spironolactone group. The number of patients with HbA(1c) 8.0% or greater increased after spironolactone treatment. A significant decrease in systolic but not in diastolic blood pressure was observed in both treatment groups. In conclusion, our data

suggest that in patients with type 2 diabetes mellitus complicated by diabetic nephropathy, spironolactone can decrease plasminogen activator inhibitor 1 and brain natriuretic peptide levels in addition to urinary albumin excretion, and systolic blood pressure, and that in patients with poor glycemic control, spironolactone can increase the levels of adiponectin and visfatin. However, the significant elevation of HbA(1c) levels by spironolactone should be emphasized. (c) 2006 Elsevier Inc. All rights reserved.

11/7/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019493026 BIOSIS NO.: 200700152767
Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance
AUTHOR: Nilsson Peter M (Reprint); Engstrom Gunnar; Hedblad Bo; Frystyk Jan
; Persson Margaretha M; Berglund Goran; Flyvbjerg Allan
AUTHOR ADDRESS: Lund Univ, Malmo Univ Hosp, Dept Clin Sci Med, S-20502 Malmo, Sweden**Sweden
AUTHOR E-MAIL ADDRESS: Peter.Nilsson@med.lu.se
JOURNAL: Arteriosclerosis Thrombosis and Vascular Biology 26 (12): p 2758-2762 DEC 2006 2006
ISSN: 1079-5642
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background - Circulating adiponectin is a marker for insulin sensitivity, derived from fat cells. It is largely unknown if adiponectin is also an independent marker for early atherosclerosis. Methods and Results - Plasma adiponectin levels were measured in 373 men and 514 women of middle-age by a time-resolved immunofluorometric assay. The subjects were sampled stratified for degree of insulin sensitivity (HOMA-IR). An ultrasound measurement of the right common carotid artery intima media thickness (IMT) was made. When the distribution of adiponectin was stratified into sex-specific quartiles (Q1 to Q4), men in Q4 differed from Q1 in higher mean age and high-density lipoprotein (HDL) cholesterol, but lower blood pressure,

HbA(1c), HOMA-index, and body mass index. Women showed similar associations. Mean IMT for men was significantly lower ($P = 0.03$) in adiponectin Q4 as compared with Q1 when adjusted for age, waist, smoking, HDL cholesterol, and diastolic blood pressure. When adding HbA1c and HOMA to the model, the association was no longer significant ($P = 0.15$). In women no difference in IMT was noticed across adiponectin quartiles. Conclusion - Plasma adiponectin is a marker of glucose metabolism and obesity and shows an inverse age-adjusted association with carotid ultrasound IMT in men, but not in women. This association is attenuated after adjustments for other risk factors.

11/7/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019464349 BIOSIS NO.: 200700124090
Role of adiponectin and its relationship to procollagen type I carboxy-terminal propeptide in essential hypertension
AUTHOR: Tsai Wei-Chuan (Reprint); Lin Chih-Chan; Lee Cheng-Han; Li Wei-Ting
; Chen Ju-Yi; Chen Jyh-Hong
AUTHOR ADDRESS: Natl Cheng Kung Univ, Med Ctr, Tainan 70101, Taiwan**Taiwan
JOURNAL: Circulation 114 (18, Suppl. S): p773-774 OCT 31 2006 2006
CONFERENCE/MEETING: 79th Annual Scientific Session of the American-Heart-Association Chicago, IL, USA November 12 -15, 2006; 20061112
SPONSOR: Amer Heart Assoc
ISSN: 0009-7322
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background: Serum concentration of procollagen type I carboxy-terminal propeptide (PICP) is proved to be a good marker for myocardial fibrosis in hypertension. Adiponectin is a cytokine from adipose tissue and decreased adiponectin level is associated with increased atherosclerosis. However, the role of adiponectin and its relationship to PICP in essential hypertension have never been studied before. Methods: This study consisted of 188 non-diabetic essential hypertensive patients (mean age 41 ± 7 years, 128 men). All of the patients did not have vascular complications; renal, or liver diseases. Serum concentrations of PICP and adiponectin were measured by enzyme-linked immunosorbent assay. Pulse wave velocity (PWV) assessed by tonometry was used as an index for aortic stiffness. Results:

Adiponectin was significantly correlated with triglyceride ($r = -0.243$, $p = 0.001$), high-density lipoprotein ($r = 0.284$, $p < 0.001$), insulin ($r = -0.169$, $p = 0.020$), and body mass index ($r = -0.208$, $p = 0.004$).
PICP was significantly correlated with PWV ($r = 0.146$, $p = 0.047$).
PICP was not correlated with blood pressure, lipid profiles, body mass index, and insulin level. However, PICP was significantly correlated with adiponectin ($r = -0.200$, $p = 0.006$). After multivariate analysis, PICP was still significantly correlated with adiponectin ($B = -0.220$, $p = 0.004$). Conclusions: Serum adiponectin levels could be a marker for metabolic syndrome in essential hypertension. Adiponectin was significantly negatively correlated with PICP. Adiponectin probably plays an important role in myocardial fibrosis as well as aortic stiffness in essential hypertension.

11/7/10 (Item 10 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.

0019462349 BIOSIS NO.: 200700122090
Adipokine resistin induces expression of adhesion molecules and tissue factor in human coronary artery endothelial cells
AUTHOR: Calabro Paolo (Reprint); Cirillo Plinio; Maddaloni Valeria; Limongelli Giuseppe; Weisz Sara; Rucco Maria Antonietta; Palmieri Rosalinda; Riegler Lucia; De Palma Raffaele; Chiarillo Massimo; Golino Paolo; Calabro Raffaella
AUTHOR ADDRESS: Second Univ Naples, Monaldi Hosp, Div Cardiol, Naples, Italy**Italy
JOURNAL: Circulation 114 (18, Suppl. S): p308 OCT 31 2006 2006
CONFERENCE/MEETING: 79th Annual Scientific Session of the American Heart Association Chicago, IL, USA November 12-15, 2006; 20061112
SPONSOR: Amer Heart Assoc
ISSN: 0009-7322
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Objective: Atherosclerosis is characterized by endothelial inflammation and dysfunction. Adipose tissue has been increasingly recognized as an active endocrine organ secreting so-called adipokines, and among them resistin is probably the latest described and the less studied. Resistin has been defined as a novel inflammatory marker in atherosclerosis and its serum levels correlate with coronary artery calcification and multivessel coronary artery disease. The

pathophysiology underlying this interplay, however, remains incompletely characterized. The aim of our study is to determine whether resistin might affect the prothrombotic and atherosclerotic characteristics of

human coronary artery endothelial cells. Methods and Results:

Incubation

of endothelial cells with resistin led to an upregulation of the expression of both ICAM-1 and VCAM-1 (CAMS) as demonstrated by FACS analysis. Moreover, tissue factor (TF) expression and activity were also

induced in a dose dependent manner, as shown by FACS analysis and real

time PCR, and a specific colorimetric assay respectively. To better investigate the intracellular mechanisms, activation of the transcription

factor, NF-kB, was demonstrated by EMSA and by suppression of CAMS and TF

expression by the NF-kB inhibitor, pyrrolidine-dithio-carbamate ammonium.

Conclusions: these data confirm that resistin may contribute to atherothrombosis exerting direct effects on human coronary endothelial

cells by promoting CAMs and TF expression, supporting the notion that

resistin, besides representing a marker of inflammation, is an effector

molecule able to induce a pro-atherothrombotic phenotype in cells of the

vessel wall. [GRAPHICS]ssion was not enhanced along with the increase of

adiponectin levels. Moreover, pretreatment with a PI3 kinase inhibitor wortmannin, but not a PPAR gamma antagonist GW9662, significantly inhibited the IL-10-induced adiponectin production. In contrast, IL-10 did not alter leptin and TNF-alpha(levels compared to

controls (238.4 +/- 8.6 vs.. 223.1 +/- 0.8 pg/ml, 396.8 +/- 18.2 vs. 407.0 +/- 21.8 pg/ml, respectively). Conclusion: IL-10 enhanced adiponectin production and PPAR gamma expression without promoting adipogenic differentiation in visceral SVCs. These results suggest the

potential for therapeutic use of IL-10 in metabolic syndrome.

? ds

Set	Items	Description
S1	475	SERUM (3N) SAMPLE (3N) (TREATMENT OR PRETREATMENT)
S2	146	RD S1 (unique items)
S3	117	S2 NOT PY>2006
S4	117	RD S3 (unique items)
S5	3720408	4 AND ACID
S6	24	S4 AND ACID
S7	3	S6 AND (IMMUNOASSAY OR ANTIBODY)

```

S8      55814    ADIPONECTIN
S9      3402    S8 AND (ASSAY OR IMMUNOASSY)
S10     1185    S9 NOT PY>2006
S11     352     RD S10 (unique items)
? s adiponectin 5n immunoassay
    S12      0    ADIPONECTIN 5N IMMUNOASSAY
? s adiponectin 10n immunoassay
    S13      0    ADIPONECTIN 10N IMMUNOASSAY
? s adiponectin and immunoassay
    55814    ADIPONECTIN
    475337   IMMUNOASSAY
    S14      510   ADIPONECTIN AND IMMUNOASSAY
? s s11 and s14
    352     S11
    510     S14
    S15     27    S11 AND S14
? rd s15

```

>>>Duplicate detection is not supported for File 393.

>>>Records from unsupported files will be retained in the RD set.

```

    S16      27    RD S15 (unique items)
? t s16/7/all

```

>>>Format 7 is not valid in file 143

```

16/7/1      (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

```

```

19193655    BIOSIS NO.: 200600539050
Determination of adiponectin in serum using a latex particle-enhanced
turbidimetric immunoassay with an automated analyzer
AUTHOR: Nishimura Ayako; Sawai Tokio (Reprint)
AUTHOR ADDRESS: Mitsubishi Kagaku Iatron Inc, Div Res and Dev, 1460-6
Mitodai, Takomachi, Chiba 2892247, Japan**Japan
AUTHOR E-MAIL ADDRESS: sawai.tokio@me.mk-iatron.co.jp
JOURNAL: Clinica Chimica Acta 371 (1-2): p163-168 SEP 2006 2006
ISSN: 0009-8981
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

```

ABSTRACT: Background: Adiponectin is an adipose-derived hormone that plays a role in regulating metabolic processes such as fat partitioning and lipid and glucose metabolism. Quantification of adiponectin is useful for obtaining information on metabolic syndrome, but there is no rapid method to measure adiponectin for clinical use. Methods: We developed a rapid and sensitive latex particle-enhanced turbidimetric immunoassay (LTIA) using a latex bead-immobilized anti-

adiponectin polyclonal antibody. The assay was performed on a Hitachi H7170 analyzer and evaluated for validity as a method to quantitate adiponectin, in parallel with the ELISA. Results: Dilution tests using LTIA showed linearity from 0.25 to 30 μ g/ml. Within-run CV and total CV were obtained in the range of 0.8-1.9% and 1.1-2.0%, respectively. No interference was observed in the testing of specimens containing potentially interfering substances such as bilirubin, ditauobilirubin, hemoglobin triglyceride, rheumatoid factor, type IV collagen, fibronectin, and complement factor (Clq). A strong correlation between LTIA and ELISA was confirmed ($n=30$, $r=0.990$, $y=0.95x+0.39$). Conclusion: The LTIA assay is applicable to quantitating the serum concentration of adiponectin. This assay is more convenient and faster than ELISA and suitable for clinical routine analysis. (c) 2006 Elsevier B.V. All rights reserved.

16/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

19120920 BIOSIS NO.: 200600466315
Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25)
AUTHOR: Lopez-Bermejo Abel (Reprint); Khosravi Javad; Fernandez-Real Jose
Manuel; Hwa Vivian; Pratt Katherine L; Casamitjana Roser; Garcia-Gill Maria M; Rosenfeld Ron G; Ricart Wifredo
AUTHOR ADDRESS: Dr Josep Trueta Hosp, Unit Diabet Endocrinol and Nutr, Av Francia S-N, Girona 17007, Spain**Spain
AUTHOR E-MAIL ADDRESS: uden.alopez@htrueta.scs.es
JOURNAL: Diabetes 55 (8): p2333-2339 AUG 2006 2006
ISSN: 0012-1797
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: IGF-binding protein (IGFBP)-related protein 1 (IGFBP-rP1) has been shown to bind both IGFs and insulin, albeit with low affinity, and to inhibit insulin signaling. We hypothesized that IGFBP-rP1 is associated with insulin resistance and components of the IGF system in humans. To this aim, a cross-sectional study was conducted in 113 nondiabetic and 43 type 2 diabetic men. Insulin sensitivity (insulin sensitivity index [Si] from intravenous glucose tolerance tests in

nondiabetic subjects, or the rate constant for disappearance of glucose [K-ITT] from insulin tolerance tests in type 2 diabetic subjects), circulating IGFBP-rP1 (from enzyme-linked immunosorbent assay), adiponectin (from radioimmunoassay), C-reactive protein (CRP; from immunoturbidimetry), soluble tumor necrosis factor receptor 2 (sTNFR2; from enzyme-amplified sensitivity immunoassay), and IGF system parameters (IGF-I, free IGF-I, and IGFBP-1 from immunoradiometric assay) were assessed in all subjects. Among nondiabetic men, those in the highest quartile for circulating IGFBP-rP1 exhibited decreased S-i and adiponectin (both $P < 0.01$) as well as increased CRP and sTNFR2 (both $P < 0.05$). Circulating IGFBP-rP1 was also found to be increased in previously undiagnosed type 2 diabetic patients ($P = 0.01$) but not in known type 2 diabetic patients receiving pharmacological therapy. Although no changes in IGF system components were evident by IGFBP-rP1 quartiles in nondiabetic subjects, independent positive associations of IGFBP-rP1 with circulating fasting IGFBP-1 were evident after adjustment for insulin resistance parameters in both nondiabetic and type 2 diabetic subjects, with IGFBP-rP1 explaining 2 and 11% of IGFBP-1 variance, respectively. In additional multivariate analyses, S-i, sTNFR2, and age stood as independent predictive variables of IGFBP-rP1 (together explaining 18% of its variance) in nondiabetic subjects, and BMI became the only independent predictive variable of IGFBP-rP1 (explaining 26% of its variance) in type 2 diabetic men. These findings show for the first time that circulating IGFBP-rP1 is increased with insulin resistance, and they also suggest novel interactions between IGFBP-rP1 and the IGF system in humans.

16/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

18992081 BIOSIS NO.: 200600337476
Preliminary investigation of blood correlates of change in adiponectin with change in body fat
AUTHOR: Wright Jennifer Anne (Reprint); May Melissa; Cussler Ellen; Lohman

Timothy; Thompson Patricia
AUTHOR ADDRESS: Univ Arizona, Tucson, AZ 85721 USA**USA
JOURNAL: FASEB Journal 20 (5, Part 2): pA1171 MAR 7 2006 2006
CONFERENCE/MEETING: Experimental Biology 2006 Meeting San Francisco, CA,
USA April 01 -05, 2006; 20060401
SPONSOR: Amer Assoc Anatomists
Amer Physiol Soc
Amer Soc Biochem & Mol Biol
Amer Soc Investigat Pathol
Amer Soc Nutr
Amer Soc Pharmacol & Expt Therapeut
ISSN: 0892-6638
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Changes in adiponectin have been associated with change in percent total body fat (%TBF), however, the relationship between estrogen and adiponectin with fat change, has not been well defined. Since elevated adiponectin is associated with diabetes risk reduction, its interaction with estrogen may be important to postmenopausal (PM) women. Therefore, a preliminary analysis of the relationship between estrogen and adiponectin was per-formed in the greatest %TBF losers (-6.8%, N=9) and gainers (4.7%, N=11) of a large randomized controlled trial of resistance training in PM women, using or not using hormone therapy. Serum estrogen and plasma adiponectin were measured by radio immunoassay and enzyme-linked immunosorbent assay, respectively. TBF was assessed by dual-energy X-ray absorptiometry. There were no significant differences between groups at baseline. Gainers of %TBF significantly decreased adiponectin in 1 year, compared to losers ($p < 0.03$). Multiple linear regression demonstrated a significant independent negative association between change in adiponectin and change in %TBF ($p < 0.01$) and, unexpectedly, an independent, positive association with change in estradiol ($p < 0.03$) and estrone ($p < 0.06$). Based on this small sample, we conclude that there may be a relationship between adiponectin and hormone levels in PM women warranting further investigation.

16/7/4 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2009 The Thomson Corp. All rts. reserv.

15502784 Genuine Article#: 076YZ Number of References: 26

Title: Roles of adipocyte derived hormone adiponectin and resistin in insulin resistance of type 2 diabetes

Author: Lu HL; Wang HW (REPRINT) ; Wen Y; Zhang MX; Lin HH

Author Email Address: hwwang@tjhu.edu.cn

Corporate Source: Huazhong Univ Sci & Technol, Dept Pediat, Tongji Hosp,

Tongji Med Coll, Wuhan 430030/Hubei Province/Peoples R China/ (REPRINT);

Huazhong Univ Sci & Technol, Dept Pediat, Tongji Hosp, Tongji Med Coll, Wuhan 430030/Hubei Province/Peoples R China/; Huazhong Univ Sci &

Technol, Dept Endocrinol, Tongji Hosp, Tongji Med Coll, Wuhan 430030/Hubei Province/Peoples R China/

Journal: WORLD JOURNAL OF GASTROENTEROLOGY, 2006, V12, N11 (MAR 21), P 1747-1751

ISSN: 1007-9327 Publication Date: 20060321

Publisher: W J G PRESS, PO BOX 2345, BEIJING 100023, PEOPLES R CHINA

Language: English Document Type: ARTICLE

Abstract: AIM: To detect plasma levels of new adipocyte derived hormone

adiponectin and resistin in type 2 diabetes patients and to explore their potential roles in insulin resistance in type 2 diabetes.

METHODS: According to the body mass index (BMI), 60 type 2 diabetes

patients were divided into two groups, one group was non-obese diabetes

patients with BMI < 25Kg/M-2 (30 cases) and the other group was obese

diabetes patients with BMI > 25Kg/M-2 (30 cases). There were 28 healthy

persons in the control group. ELISA technique was employed to determine

the plasma adiponectin and resistin concentrations. The fasting blood glucose, insulin and blood lipid were detected respectively by

electrocheminescence immunoassay and immunoturbidimetric assay. Insulin resistance index and insulin sensitive index were calculated by the homeostasis model assessment (HOMO).

RESULTS: The levels of plasma adiponectin were decreased significantly in diabetes group compared to that in control group (non-obese: 8.58 +/- 0.86, obese: 6.22 +/- 1.34 vs 10.53 +/- 1.47 P < 0.05); moreover, adiponectin concentration in obese diabetes group was significantly decreased compared to that in non-obese diabetes group (6.22 +/- 1.34 vs 8.58 +/- 0.86, P < 0.05). The levels

of plasma resistin were increased significantly in diabetes group compared to that in control group (obese: 18.64 +/- 4.65, non-obese:

24.05

+/- 9.07 vs 14.16 +/- 5.25, $P < 0.05$, $P < 0.05$); furthermore, the levels of resistin in obese diabetes group were increased significantly compared to that in non-obese diabetes group ($P < 0.05$). Plasma adiponectin was correlated negatively with BMI, blood glucose, insulin resistance index and triglyceride (respectively, $r = -0.55$, $P < 0.01$; $r = -0.51$, $P < 0.05$; $r = -0.52$, $P < 0.05$; $r = -0.39$, $P < 0.05$), while it was positively correlated with insulin sensitive index ($r = 0.45$, $P < 0.05$). Conversely, plasma resistin correlated positively with BMI, blood glucose, triglyceride and insulin resistance index (respectively, $r = 0.40$, $P < 0.05$; $r = 0.52$, $P < 0.05$; $r = 0.46$, $P < 0.01$; $r = 0.27$, $P < 0.05$), and negatively correlated with insulin sensitive index ($r = -0.32$, $P < 0.05$).

CONCLUSION: Plasma adiponectin and resistin are associated with the disorder of metabolism of glucose and lipid in diabetes. The relationship between these hormone and insulin sensitivity suggests that they may take part in the development of insulin resistance of type 2 diabetes. (c) 2006 The WJG Press. All rights reserved.

16/7/5 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0006718506 SUPPLIER NUMBER: 2006219914
Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer
Nishimura A.; Sawai T.
AUTHOR EMAIL: sawai.tokio@me.mk-iatron.co.jp
CORRESP. AUTHOR/AFFIL: Sawai T., Division of Research, Development
Mitsubishi Kagaku Iatron Inc., 1460-6 Mitodai, Tako-machi,
Katori-gun,
Chiba-ken, 289-2247, Japan
CORRESP. AUTHOR EMAIL: sawai.tokio@me.mk-iatron.co.jp
Journal: Clinica Chimica Acta (Clin. Chim. Acta), v371, n1-2,
(163-168),
2006, Netherlands
PUBLICATION DATE: September 1, 2006 (20060901)
CODEN: CCATA
ISSN: 0009-8981 eISSN: 1097-0169
DOI: <http://dx.doi.org/10.1016/j.ccca.2006.03.008>
PUBLISHER ITEM IDENTIFIER: S0009898106001641
RECORD TYPE: Abstract; New
DOCUMENT TYPE: Article

LANGUAGES: English

SUMMARY LANGUAGES: English

NO. OF REFERENCES: 24

Background: Adiponectin is an adipose-derived hormone that plays a role in regulating metabolic processes such as fat partitioning and lipid

and glucose metabolism. Quantification of adiponectin is useful for obtaining information on metabolic syndrome, but there is no rapid method

to measure adiponectin for clinical use. Methods: We developed a rapid and sensitive latex particle-enhanced turbidimetric immunoassay (LTIA) using a latex bead-immobilized anti-adiponectin polyclonal antibody. The assay was performed on a Hitachi H7170 analyzer and evaluated for validity as a method to quantitate adiponectin, in parallel with the ELISA. Results: Dilution tests using LTIA showed linearity from 0.25 to 30 $\mu\text{g}/\text{ml}$. Within-run CV and total CV were obtained

in the range of 0.8-1.9% and 1.1-2.0%, respectively. No interference was

observed in the testing of specimens containing potentially interfering

substances such as bilirubin, ditauobilirubin, hemoglobin triglyceride,

rheumatoid factor, type IV collagen, fibronectin, and complement factor

(Clq). A strong correlation between LTIA and ELISA was confirmed ($n = 30$, r

$= 0.990$, $y = 0.95x + 0.39$). Conclusion: The LTIA assay is applicable to quantitating the serum concentration of adiponectin. This assay is more convenient and faster than ELISA and suitable for clinical routine analysis. (c) 2006 Elsevier B.V. All rights reserved.

16/7/6 (Item 1 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 2009 Elsevier B.V. All rts. reserv.

0081458323 EMBASE No: 2006521414

Serum adiponectin levels and enzyme markers of liver dysfunction in diabetic and non-diabetic Caribbean subjects

Ezenwaka C.E.; Kallou R.; Uhlig M.; Schwenk R.; Eckel J.

Unit of Pathology and Microbiology, Faculty of Medical Sciences,

University of the West Indies, St. Augustine, Trinidad and Tobago

AUTHOR EMAIL: cezenwaka@fms.uwi.tt

CORRESP. AUTHOR/AFFIL: Ezenwaka C.E.: Unit of Pathology and Microbiology,

Faculty of Medical Sciences, University of the West Indies, St. Augustine,

Trinidad and Tobago

CORRESP. AUTHOR EMAIL: cezenwaka@fms.uwi.tt

British Journal of Biomedical Science (Br. J. Biomed. Sci.)
(United

Kingdom) November 6, 2006, 63/3 (117-122)
CODEN: BJMSE ISSN: 0967-4845
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 28

Low adiponectin levels are associated with elevated plasma alanine aminotransferase, a marker of reduced hepatic insulin sensitivity and a

risk factor for type 2 diabetes. This study aims to determine the relationship between serum adiponectin level and alanine aminotransferase in diabetic and non-diabetic subjects. Fifty-six type 2

diabetic patients and 33 non-diabetic subjects participate in the study.

Baseline plasma concentrations of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and glucose are measured on a chemistry analyser. Insulin and adiponectin are measured using enzyme-linked immunoassay techniques and insulin resistance is determined using the homeostatic model assessment method. Diabetic patients

showed significantly lower levels of serum adiponectin than did the non-diabetic subjects, whereas levels of alanine aminotransferase and alkaline phosphatase were similar in both groups. While female non-diabetic

subjects showed higher serum adiponectin levels than did female diabetic patients, alanine aminotransferase level did not differ ($P>0.05$).

No significant relationship was seen between adiponectin and alanine aminotransferase in diabetic and non-diabetic subjects ($P>0.05$). Serum adiponectin levels were higher in non-diabetic subjects but there was no significant correlation between adiponectin and alanine aminotransferase in both groups of subjects. The data suggest that low serum adiponectin level may not be a suitable marker for impaired liver function in diabetic patients.

16/7/7 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0081228170 EMBASE No: 2006290340

Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in south-Asians

Wasim H.; Al-Daghri N.M.; Chetty R.; McTernan P.G.; Barnett A.H.; Kumar S.

Queen Elizabeth Hospital, Birmingham University, Birmingham, United Kingdom

AUTHOR EMAIL: Wasim.Hanif@uhb.nhs.uk; aldaghr2000@hotmail.com; nma@myway.com; P.G.McTernan@warwick.ac.uk; aldaghi2000@hotmail.com; Sudhesh.Kumar@warwick.ac.uk

CORRESP. AUTHOR/AFFIL: Al-Daghri N.M.: King Saud University,
College of
Science, Biochemistry Department, Riyadh, Saudi Arabia
CORRESP. AUTHOR EMAIL: aldaghri2000@hotmail.com

Cardiovascular Diabetology (Cardiovasc. Diabetol.) (United
Kingdom)

May 2, 2006, 5/-

CODEN: CDAIA ISSN: 1475-2840 eISSN: 1475-2840

DOI: 10.1186/1475-2840-5-10

URL: <http://www.cardiab.com/content/5/1/10>

ARTICLE NUMBER: 10

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 38

Objectives: South-Asians have lower adiponectin levels compared to Caucasians. It was not clear however, if this intrinsic feature is related to aspects of glucose metabolism. This study aims to determine the relationship between body fat distribution and adipocytokine in South-Asian subjects by measuring serum adipocytokines, adiposity, insulinemia, and glucose tolerance levels. Methods: In this cross-sectional study, 150 South-Asians (80 males, 70 females) were included, 60 had NGT (Control group, Age 51.33 +/- 11.5, BMI 27 +/- 2.3), 60 had IGT (Age 57.7 +/- 12.5, BMI 27.2 +/- 2.7), 30 had type 2 DM (Age 49.5 +/- 10.9, BMI 28 +/- 1.7). Measures of adiposity, adipocytokines and other metabolic parameters were determined. Parameters were measured using the following: a) Plasma glucose by glucose oxidase method b) CRP by immunoturbidimetric method (Roche/Hitachi analyser) c) insulin by Medgenix INS-ELISA immunoenzymetric assay by Biosource (Belgium) d) Leptin, Adiponectin by radioimmunoassay kits by Linco Research (St. Charles MO) e) Resistin by immunoassay kits by Phoenix Pharmaceuticals INC (530 Harbor Boulevard, Belmont CA 94002, USA). Results: Adiponectin concentrations were highest in NGT, decreased in IGT and lowest in DMT2, (both $p < 0.01$). Leptin was significantly higher in DMT2 than IGT and NGT $p = 0.02$ and 0.04 respectively. There was a significant positive relationships between log adiponectin and 2-hr insulin values, $p = 0.028$ and history of hypertension and a ischemic heart disease $p = 0.008$ with $R = 0.65$. There was a significant inverse correlation between log adiponectin and resistin, $p < 0.01$. Conclusion: Resistin levels had

an inverse correlation with adiponectin levels, indicating an inverse relationship between pro-inflammatory cytokines and adiponectin. Adiponectin levels were related to glucose tolerance. (c) 2006 Wasim et al; licensee BioMed Central Ltd.

16/7/8 (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 2009 Dialog. All rts. reserv.

17249907 PMID: 16759463

[Study on the relationship between serum adiponectin and insulin resistance in women with polycystic ovary syndrome]

Yang Xue-feng; Ren Fen-ruo; Guo Shu-ping

Department of Obstetrics and Gynecology, Third Affiliated Hospital,
Zhengzhou University, Zhengzhou 450052, China.

Zhonghua fu chan ke za zhi (China) Apr 2006, 41 (4) p261-3,
ISSN

0529-567X--Print Journal Code: 16210370R

Publishing Model Print

Document type: English Abstract; Journal Article; Research Support,

Non-U.S. Gov't

Languages: CHINESE

Main Citation Owner: NLM

Record type: MEDLINE; Completed

OBJECTIVE: To study the relationship between serum adiponectin and insulin resistance in women with polycystic ovary syndrome (PCOS).

METHODS:

Forty women with PCOS and twenty five healthy women were divided into PCOS

obese group [body weight index (BMI) \geq 25kg/m²], PCOS non-obese

group (BMI < 25 kg/m²) and control group. There are 19 cases in PCOS

obese group and 21 cases in PCOS non-obese group, 9 cases in obese control

group and 16 in non-obese control group. Serum adiponectin levels of the four groups were detected by enzyme linked immunosorbent assay (ELISA) method, insulin by electrochemiluminescence immunoassay method, blood sugar by glucose oxidation enzyme method, tumor necrosis

factor-alpha (TNF-alpha) by radioimmunoassay. Insulin sensitivity index

(ISI) was calculated. RESULTS: (1) Serum adiponectin levels of PCOS obese group was (1.6 \pm 0.5) mg/L, of PCOS non-obese group was

(3.0 \pm 0.6) mg/L. Their values were lower than obese control group (3.2 \pm 0.3)

mg/L, and non-obese control group (4.9 \pm 0.5) mg/L (P < 0.05). (2)

Fasting insulin levels of PCOS obese group was (17 +/- 6) mU/L, PCOS non-obese group was (14 +/- 6) mU/L. They were higher than obese control group (10 +/- 3) mU/L, and non-obese control group (7 +/- 3) mU/L (P < 0.05). (3) Fasting blood sugar level was (5.2 +/- 0.7) mmol/L in PCOS obese group, in PCOS non-obese group was (5.1 +/- 0.6) mmol/L, in obese control group was (5.4 +/- 0.5) mmol/L, and non-obese control group (4.8 +/- 0.6) mmol/L, without marked difference among four groups. (4) TNF-alpha levels of PCOS obese group was (1.32 +/- 0.14) microg/L, of PCOS non-obese group was (1.02 +/- 0.12) microg/L. They were higher than obese control group (0.93 +/- 0.15) microg/L, and non-obese control group (0.63 +/- 0.18) microg/L (P < 0.05). (5) ISI of PCOS obese group was -4.5 +/- 0.3, PCOS non-obese group was -4.1 +/- 0.4. Their values were lower than obese control group -3.6 +/- 0.3, and non-obese control group (-3.1 +/- 0.4) (P < 0.05). Serum adiponectin levels of the women with PCOS were correlated negatively with BMI (r = -0.56, P < 0.05), and correlated positively with ISI (r = 0.49, P < 0.05). CONCLUSION: Serum adiponectin levels of women with PCOS is decreased compared with healthy women, particularly in obese women with PCOS. The decrease is correlated with ISI.

Record Date Created: 20060608

Record Date Completed: 20080214

16/7/9 (Item 2 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 2009 Dialog. All rts. reserv.

17031789 PMID: 16427606

Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes.

Chen Baoying; Lam Karen S L; Wang Yu; Wu Donghai; Lam Michael C; Shen

Jiangang; Wong Laiching; Hoo Ruby L C; Zhang Jialiang; Xu Aimin
Department of Medicine, University of Hong Kong, Hong Kong, China.
Biochemical and biophysical research communications (United States)
Mar

Publishing Model Print-Electronic

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Low plasma levels of adiponectin (hypoadiponectinemia) and elevated circulating concentrations of plasminogen activator inhibitor (PAI)-1 are

causally associated with obesity-related insulin resistance and

cardiovascular disease. However, the mechanism that mediates the aberrant

production of these two adipokines in obesity remains poorly understood. In

this study, we investigated the effects of hypoxia and reactive oxygen

species (ROS) on production of adiponectin and PAI-1 in 3T3-L1 adipocytes. Quantitative PCR and immunoassays showed that ambient hypoxia

markedly suppressed adiponectin mRNA expression and its protein secretion, and increased PAI-1 production in mature adipocytes.

Dimethylloxallyl glycine, a stabilizer of hypoxia-inducible factor 1alpha

(HIF-1alpha), mimicked the hypoxia-mediated modulations of these two

adipokines. Hypoxia caused a modest elevation of ROS in adipocytes.

However, ablation of intracellular ROS by antioxidants failed to alleviate

hypoxia-induced aberrant production of adiponectin and PAI-1. On the other hand, the antioxidants could reverse hydrogen peroxide (H2O2)-induced

dysregulation of adiponectin and PAI-1 production. H2O2 treatment decreased the expression levels of peroxisome proliferator-activated

receptor gamma (PPARGgamma) and CCAAT/enhancer binding protein (C/EBPalpha),

but had no effect on HIF-1alpha, whereas hypoxia stabilized HIF-1alpha and

decreased expression of C/EBPalpha, but not PPARGgamma. Taken together,

these data suggest that hypoxia and ROS decrease adiponectin production and augment PAI-1 expression in adipocytes via distinct

signaling pathways. These effects may contribute to hypoadiponectinemia and

elevated PAI-1 levels in obesity, type 2 diabetes, and cardiovascular

diseases.

Record Date Created: 20060131
Record Date Completed: 20060418
Date of Electronic Publication: 20060113

16/7/10 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

147498180 CA: 147(24)498180j JOURNAL
Quickly detecting the content of plasma Acrp30 by competitive ELISA
AUTHOR(S): Hu, Xiaobo; Yan, Zhiqiang; Chen, Xia; Yang, Shengli; Xu,
Jinhua; Gong, Yi
LOCATION: Shanghai Institutes for Biological Sciences, Chinese
Academy of
Science, Shanghai, Peop. Rep. China, 200233
JOURNAL: Nanhua Daxue Xuebao, Yixueban (Nanhua Daxue Xuebao,
Yixueban)
DATE: 2006 VOLUME: 34 NUMBER: 1 PAGES: 37-39,43 CODEN: NDXYAD
ISSN:
1672-7444 LANGUAGE: Chinese PUBLISHER: Nanhua Daxue Jikanshe
SECTION:
CA209010 Biochemical Methods
CA213XXX Mammalian Biochemistry
IDENTIFIERS: adiponectin globular head domain immunogen competitive
ELISA
blood antigen
DESCRIPTORS:
Protein motifs...
C-terminal globular head domain of Acrp30; quickly detecting the
content of plasma Acrp30 by competitive ELISA
Enzyme-linked immunosorbent assay...
competitive; quickly detecting the content of plasma Acrp30 by
competitive ELISA
Adiponectins... Antigens... Antiserums... Blood plasma...
Immunoassay...
Oryctolagus cuniculus... Rabbit...
quickly detecting the content of plasma Acrp30 by competitive
ELISA
Proteins...
recombinant, Acrp30; quickly detecting the content of plasma
Acrp30 by
competitive ELISA
CAS REGISTRY NUMBERS:
7664-93-9 uses, quickly detecting the content of plasma Acrp30 by
competitive ELISA

16/7/11 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

145389427 CA: 145(20)389427h PATENT

Inhibition of wet type age related macular degeneration (amd) by adiponectin or acrp 30

INVENTOR(AUTHOR): Bora, Puran S.; Bora, Nalini S.; Kaplan, Henry J.

LOCATION: USA

ASSIGNEE: University of Louisville Research Foundation, Inc.

PATENT: PCT International ; WO 2006104964 A2 DATE: 20061005

APPLICATION: WO 2006US11008 (20060322) *US 2005PV665702 (20050328)

PAGES: 34pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0038/17 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR;

BW; BY;

BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI;

GB; GD;

GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ;

LC; LK;

LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI;

NO; NZ;

OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM;

TN; TR;

TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE;

BG; CH

; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV;

MC;

NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ;

GW; ML;

MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ;

UG; ZM;

ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

SECTION:

CA201012 Pharmacology

CA202XXX Mammalian Hormones

IDENTIFIERS: wet age macular degeneration adiponectin, peptide choroidal

neovascularization inhibitor

DESCRIPTORS:

Cytokines...

adiponectin, expression in laser-induced mouse model of wet type age

related macular degeneration; inhibition of wet type age related macular degeneration by adiponectin

Cytokines...

adiponectin, functional fragment; inhibition of wet type age related

macular degeneration by adiponectin

Cytokines...

adiponectin; inhibition of wet type age related macular degeneration by

adiponectin

Eye...

angiogenesis in; inhibition of wet type age related macular degeneration by adiponectin
Animal cell... Animal tissue...
angiogenesis in; inhibition of wet type age related macular degeneration by adiponectin
Drug delivery systems...
carriers; inhibition of wet type age related macular degeneration by adiponectin
Eye...
choroid, adiponectin expression in; decrease in AMD mouse model; inhibition of wet type age related macular degeneration by adiponectin
Eye...
choroid, angiogenesis; inhibition of wet type age related macular degeneration by adiponectin
Eye...
ciliary body, adiponectin expression in; inhibition of wet type age related macular degeneration by adiponectin
Eye...
cornea, adiponectin expression in; inhibition of wet type age related macular degeneration by adiponectin
Immunoassay...
enzyme-linked immunosorbent assay; inhibition of wet type age related macular degeneration by adiponectin
Angiogenesis... Angiogenesis inhibitors... Protein sequences...
Peptides, biological studies... Diagnosis... Biomarkers...
Immunoblotting...
Northern blot hybridization...
inhibition of wet type age related macular degeneration by adiponectin
Drug delivery systems...
injections, i.p.; inhibition of wet type age related macular degeneration by adiponectin
Drug delivery systems...
injections, intravitreally; inhibition of wet type age related macular degeneration by adiponectin
Eye...
iris, adiponectin expression in; inhibition of wet type age related macular degeneration by adiponectin
Eye, disease...
macula, senile degeneration, wet type; inhibition of wet type age related macular degeneration by adiponectin
Angiogenesis...
neovascularization, retinal; inhibition of wet type age related macular

degeneration by adiponectin
Eye...
pigment epithelium; inhibition of wet type age related macular
degeneration by adiponectin
Eye,disease...
retina, neovascularization; inhibition of wet type age related
macular
degeneration by adiponectin
Epithelium...
retinal pigment; inhibition of wet type age related macular
degeneration by adiponectin
PCR(polymerase chain reaction)...
RT-PCR (reverse transcription-PCR); inhibition of wet type age
related
macular degeneration by adiponectin
CAS REGISTRY NUMBERS:
127464-60-2 106096-92-8 expression in laser-induced mouse model of
wet
type age related macular degeneration; inhibition of wet type age
related macular degeneration by adiponectin
911196-25-3 911196-26-4 911196-27-5 inhibition of wet type age
related
macular degeneration by adiponectin
911526-58-4 911526-59-5 911526-60-8 911526-61-9 911526-62-0
911526-63-1 unclaimed nucleotide sequence; inhibition of wet
type age
related macular degeneration (amd) by adiponectin or acrp 30
911196-25-3D 911196-26-4D 911196-27-5D variant, inhibition of wet
type
age related macular degeneration by adiponectin

16/7/12 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

145331020 CA: 145(17)331020d JOURNAL
Fundamental study of adiponectin of the high molecular weight for a
checkup by mail
AUTHOR(S): Miyake, Chieko; Shioya, Harumi; Kasugai, Tatsuzou
LOCATION: Aichi Medical Foundation of Diagnostic Technology, 4-23-2
Chiyoda, Naka-ku, Nagoya-shi, Aichi, Japan, 460-0012
JOURNAL: Iryo to Kensa Kiki-Shiyaku (Iryo to Kensa Kiki-Shiyaku)
DATE:
2005 VOLUME: 28 NUMBER: 6 PAGES: 535-543 CODEN: IKKRAN ISSN:
1347-0434
LANGUAGE: Japanese PUBLISHER: Rinsho Byori Kankokai
SECTION:
CA209010 Biochemical Methods
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: adiponectin plasma ELISA dry blood paper metabolic
syndrome

DESCRIPTORS:

Cytokines...

adiponectin; ELISA fundamental study of adiponectin of high mol. wt.

for checkup by mail

Blood analysis...

ELISA fundamental study of adiponectin of high mol. wt. for checkup by mail

Immunoassay...

enzyme-linked immunosorbent assay; ELISA fundamental study of adiponectin of high mol. wt. for checkup by mail

Metabolic disorders...

metabolic syndrome X; ELISA fundamental study of adiponectin of high mol. wt. for checkup by mail

16/7/13 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

145058842 CA: 145(4)58842e PATENT

Multiplexed assay methods for analytes of different abundances using immunoassays combined with electrochemiluminescence

INVENTOR(AUTHOR): Stromgren, Selen A.; Glezer, Eli N.

LOCATION: USA

ASSIGNEE: Meso Scale Technologies, LLC.

PATENT: U.S. Pat. Appl. Publ. ; US 20060134712 A1 DATE: 20060622

APPLICATION: US 2005249077 (20051012) *US 2004PV618713 (20041014)

PAGES: 13 pp. CODEN: USXXCO LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 435007920

IPCR/8	+	Level	Value	Position	Status	Version	Action	Source	Office:
--------	---	-------	-------	----------	--------	---------	--------	--------	---------

G01N-0033/537	A	I	F	B	20060101	20060622	H	US	
---------------	---	---	---	---	----------	----------	---	----	--

G01N-0033/53	A	I	L	B	20060101	20060622	H	US	
--------------	---	---	---	---	----------	----------	---	----	--

G01N-0033/543	A	I	L	B	20060101	20060622	H	US	
---------------	---	---	---	---	----------	----------	---	----	--

SECTION:

CA209010 Biochemical Methods

IDENTIFIERS: immunofluorescence assay analyte concn

DESCRIPTORS:

Cytokines...

adiponectin; multiplexed assay methods for analytes of different abundances using immunoassays combined with

electrochemiluminescence

Chemiluminescence...

electrochemiluminescence; multiplexed assay methods for analytes

of

different abundances using immunoassays combined with electrochemiluminescence

Immunoassay...

enzyme-linked immunosorbent assay; multiplexed assay methods for

analytes of different abundances using immunoassays combined with
electrochemiluminescence
Glass,uses... Fluorescence immunoassay... Magnetic particles...
Dilution...
Concentration(condition)...
multiplexed assay methods for analytes of different abundances
using
immunoassays combined with electrochemiluminescence
CAS REGISTRY NUMBERS:
9004-10-8 analysis, multiplexed assay methods for analytes of
different
abundances using immunoassays combined with
electrochemiluminescence
482618-42-8 169494-85-3 multiplexed assay methods for analytes of
different abundances using immunoassays combined with
electrochemiluminescence

16/7/14 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

144428491 CA: 144(23)428491a PATENT
Methods and compositions for diagnosis, stratification, and
monitoring of
Alzheimer's disease and other neurological disorders in body fluids
INVENTOR(AUTHOR): Ray, Sandip; Wyss-Coray, Anton
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20060094064 A1 DATE: 20060504
APPLICATION: US 2005148595 (20050608) *US 2003PV523796 (20031119)
*US
2004PV566783 (20040430) *US 2004PV566782 (20040430) *US 2004993813
(20041119)
PAGES: 52 pp., Cont.-in-part of U.S. Ser. No. 993,813. CODEN:
USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007200
IPCR/8 + Level Value Position Status Version Action Source Office:
G01N-0033/53 A I F B 20060101 20060504 H US
G01N-0033/567 A I L B 20060101 20060504 H US
SECTION:
CA209010 Biochemical Methods
CA202XXX Mammalian Hormones
CA214XXX Mammalian Pathological Biochemistry
CA215XXX Immunochemistry
IDENTIFIERS: immunoassay biomarker Alzheimer disease diagnosis
DESCRIPTORS:
Cytokines...
adiponectin; methods and immunoassays for diagnosis,
stratification and
monitoring of Alzheimer's disease and other neurol. disorders in
body

- fluids
- Growth factor receptors... Tyrosine kinase receptors...
 - Axl; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in
- body
 - fluids
- Platelet-derived growth factors...
 - BB; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in
- body
 - fluids
- Transforming growth factors...
 - β -; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in
- body
 - fluids
- Transforming growth factors...
 - $\beta 3$ -; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in
- body
 - fluids
- Neurotrophic factors...
 - brain-derived; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in
- body fluids
- Proteins...
 - BTC; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in
- body
 - fluids
- Chemokines...
 - CCL17 (C-C motif ligand 17); methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in body fluids
- CD antigens...
 - CD54; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in
- body
 - fluids
- Nervous system,disease...
 - degeneration; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in
- body fluids
- Immunoassay...
 - enzyme-linked immunosorbent assay; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and

other neurol. disorders in body fluids
Interferons...
 γ; methods and immunoassays for diagnosis, stratification and
 monitoring of Alzheimer's disease and other neurol. disorders in
body
 fluids
Cell adhesion molecules...
 ICAM-1 (intercellular adhesion mol. 1); methods and immunoassays
for
 diagnosis, stratification and monitoring of Alzheimer's disease
and
 other neurol. disorders in body fluids
Insulin-like growth factor-binding proteins...
 IGFBP-1; methods and immunoassays for diagnosis, stratification
and
 monitoring of Alzheimer's disease and other neurol. disorders in
body
 fluids
Insulin-like growth factor-binding proteins...
 IGFBP-2; methods and immunoassays for diagnosis, stratification
and
 monitoring of Alzheimer's disease and other neurol. disorders in
body
 fluids
Insulin-like growth factor-binding proteins...
 IGFBP-4; methods and immunoassays for diagnosis, stratification
and
 monitoring of Alzheimer's disease and other neurol. disorders in
body
 fluids
Chemokines...
 lymphotactin; methods and immunoassays for diagnosis,
stratification
 and monitoring of Alzheimer's disease and other neurol. disorders
in
 body fluids
Proteins...
 macrophage-stimulating, α-chain; methods and immunoassays for
 diagnosis, stratification and monitoring of Alzheimer's disease
and
 other neurol. disorders in body fluids
Macrophage inflammatory protein 4... Hepatocyte growth factor...
Lymphotoxin... Interleukin 6 receptors... Ciliary neurotrophic
factor...
Interleukin 8... Interleukin 11... Test kits... Antibodies and
Immunoglobulins... Blood analysis... Human... Biomarkers...
Alzheimer's
disease... Bone morphogenetic protein 6... Bone morphogenetic protein
4...
Eotaxin 2... RANTES(chemokine)... Urokinase-type plasminogen activator
receptors... Neutrophil-activating peptide-2... Interleukin 1 receptor
antagonist... Interleukin 3... Monocyte chemoattractant protein-1...

Macrophage inflammatory protein 1 β ... Fas antigen... Epidermal growth factor receptors... Monocyte chemoattractant protein-2...
 Immunoassay...
 methods and immunoassays for diagnosis, stratification and monitoring
 of Alzheimer's disease and other neurol. disorders in body fluids
 Chemokines...
 SDF-1 (stromal-derived factor-1); methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease
 and
 other neurol. disorders in body fluids
 Proteins...
 SR; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in
 body
 fluids
 Cytokine receptors...
 TRAIL-R3; methods and immunoassays for diagnosis, stratification
 and
 monitoring of Alzheimer's disease and other neurol. disorders in
 body
 fluids
 Tumor necrosis factor receptors...
 type 2, sol.; methods and immunoassays for diagnosis,
 stratification
 and monitoring of Alzheimer's disease and other neurol. disorders
 in
 body fluids
 Macrophage inflammatory proteins...
 18; methods and immunoassays for diagnosis, stratification and
 monitoring of Alzheimer's disease and other neurol. disorders in
 body
 fluids
 CAS REGISTRY NUMBERS:
 143011-72-7 250740-90-0 140208-24-8 124861-55-8 169494-85-3
 62229-50-9
 130939-66-1 130939-41-2 106096-93-9 123584-45-2 192662-83-2
 67763-96-6 194368-66-6 410093-94-6 9014-42-0 83869-56-1
 methods
 and immunoassays for diagnosis, stratification and monitoring of
 Alzheimer's disease and other neurol. disorders in body fluids

16/7/15 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

144382055 CA: 144(21)382055f JOURNAL
 Human adiponectin ELISA kit for total and multimers
 AUTHOR(S): Abe, Satoko
 LOCATION: Daiichi Pure Chemicals, Japan,
 JOURNAL: BIO Clin. (BIO Clinica) DATE: 2006 VOLUME: 21 NUMBER: 1

PAGES: 59-62 CODEN: BCILCY ISSN: 0919-8237 LANGUAGE: Japanese
PUBLISHER: Hokuryukan
SECTION:

CA202000 Mammalian Hormones

IDENTIFIERS: review blood adiponectin detn ELISA

DESCRIPTORS:

Cytokines...

adiponectin; ELISA kit for detn. of blood total and multimers of human

adiponectin

Blood analysis... Human...

ELISA kit for detn. of blood total and multimers of human
adiponectin

Immunoassay...

enzyme-linked immunosorbent assay; ELISA kit for detn. of blood
total
and multimers of human adiponectin

16/7/16 (Item 7 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

143114066 CA: 143(7)114066c PATENT

Systems and methods for characterizing kidney diseases

INVENTOR(AUTHOR): Hu, Huaizhong; Knechtle, Stuart; Aizenstein,

Brian D.

LOCATION: USA

ASSIGNEE: Renovar Incorporated

PATENT: U.S. Pat. Appl. Publ. ; US 20050158801 A1 DATE: 20050721

APPLICATION: US 200410685 (20041213) *US 2002313807 (20021206) *US
2004903797 (20040730)

PAGES: 31 pp., Cont.-in-part of U.S. Ser. No. 9037,97. CODEN:

USXXCO

LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 435007200; G01N-033/53A; G01N-033/567B; G01N-033/537B;
G01N-033/543B

SECTION:

CA215008 Immunochemistry

CA209XXX Biochemical Methods

CA214XXX Mammalian Pathological Biochemistry

IDENTIFIERS: system characterizing kidney disease

DESCRIPTORS:

Cytokines...

adiponectin; systems and methods for characterizing kidney
diseases

Diagnosis...

agents; systems and methods for characterizing kidney diseases
Transplant and Transplantation... Transplant rejection...

allograft; systems and methods for characterizing kidney
diseases

Immunoassay...
enzyme-linked immunosorbent assay; systems and methods for
characterizing kidney diseases

Cytometry...
flow; systems and methods for characterizing kidney diseases

Kidney,disease... Inflammation...
glomerulonephritis; systems and methods for characterizing kidney
diseases

Insulin-like growth factor-binding proteins...
IGFBP-1; systems and methods for characterizing kidney diseases

Insulin-like growth factor-binding proteins...
IGFBP-2; systems and methods for characterizing kidney diseases

Insulin-like growth factor-binding proteins...
IGFBP-6; systems and methods for characterizing kidney diseases

Immunoassay...
immunopptn.; systems and methods for characterizing kidney
diseases

Chemokines...
interferon γ -inducible protein-10; systems and methods for
characterizing kidney diseases

Transplant and Transplantation...
kidney, rejection, urine IP-10 chemokine in relation to; systems
and
methods for characterizing kidney diseases

Chemokines...
Mig (monokine induced by interferon- γ); systems and methods for
characterizing kidney diseases

BK virus...
nephritis from infection with; systems and methods for
characterizing
kidney diseases

Proteins...
Osteoprotegerin; systems and methods for characterizing kidney
diseases

Immunoassay...
radioimmunoassay; systems and methods for characterizing kidney
diseases

Injury... Injury...
renal tubular; systems and methods for characterizing kidney
diseases

Tumor necrosis factors...
sR1; systems and methods for characterizing kidney diseases

Interleukin 8... Monocyte chemoattractant protein-1...

Kidney,disease...
Test kits... Urine analysis... Statistical analysis... Microarray
technology... Microspheres... Blood serum... Blood analysis...

Macrophage
inflammatory protein 1 α ... Macrophage inflammatory protein 1 β ...
Antibodies and Immunoglobulins... Macrophage inflammatory protein 3 α
...
systems and methods for characterizing kidney diseases

Kidney...

transplant, rejection, urine IP-10 chemokine in relation to;
systems
and methods for characterizing kidney diseases
Kidney,disease... Kidney,disease...
tubular injury; systems and methods for characterizing kidney
diseases
Kidney,disease...
tubulointerstitial; systems and methods for characterizing kidney
diseases
Proteins...
uPAR; systems and methods for characterizing kidney diseases
CAS REGISTRY NUMBERS:
169494-85-3 60-27-5 systems and methods for characterizing kidney
diseases

16/7/17 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

143022448 CA: 143(2)22448a JOURNAL
Assay performance of "human adiponectin ELISA kit" and evaluation
of high
molecular weight form of adiponectin
AUTHOR(S): Akamatsu, Suguru; Sakamoto, Yuichi
LOCATION: Department of New Products Development, Otsuka Life
Science
Initiative, Otsuka Pharmaceutical Co., Ltd., Japan,
JOURNAL: BIO Clin. (BIO Clinica) DATE: 2004 VOLUME: 19 NUMBER: 13
PAGES: 1094-1099 CODEN: BCILCY ISSN: 0919-8237 LANGUAGE: Japanese
PUBLISHER: Hokuryukan
SECTION:
CA209010 Biochemical Methods
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: human adiponectin ELISA kit assay assessment
DESCRIPTORS:
Adipose tissue...
adipocyte, white; assay performance of human adiponectin ELISA
kit and
evaluation of high mol. wt. form of adiponectin
Cytokines...
adiponectin; assay performance of human adiponectin ELISA kit and
evaluation of high mol. wt. form of adiponectin
Human... Test kits... Diagnosis...
assay performance of human adiponectin ELISA kit and evaluation
of high
mol. wt. form of adiponectin
Immunoassay...
enzyme-linked immunosorbent assay; assay performance of human
adiponectin ELISA kit and evaluation of high mol. wt. form of
adiponectin
Molecular weight...

heterogeneities by difference in; assay performance of human adiponectin ELISA kit and evaluation of high mol. wt. form of adiponectin

16/7/18 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

142407211 CA: 142(22)407211c PATENT
Method of separating and assaying adiponectin multimer
INVENTOR(AUTHOR): Ebinuma, Hiroyuki; Yago, Hirokazu; Akimoto, Yuka;
Miyazaki, Osamu; Kadowaki, Takashi; Yamauchi, Toshimasa; Hara, Kazuo
LOCATION: Japan,
ASSIGNEE: Daiichi Pure Chemicals Co., Ltd.; Toudai Tlo, Ltd.
PATENT: PCT International ; WO 200538457 A1 DATE: 20050428
APPLICATION: WO 2004JP15260 (20041015) *JP 2003354930 (20031015)
PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: Japanese
PATENT CLASSIFICATIONS:
CLASS: G01N-033/53A; G01N-027/447B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI;
GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK;
LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG;
PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA;
UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS;
MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM;
AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU;
MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR;
NE; SN; TD; TG

SECTION:

CA209016 Biochemical Methods

CA214XXX Mammalian Pathological Biochemistry

IDENTIFIERS: adiponectin ELISA proteinase sepg multimer human blood
disease diagnosis

DESCRIPTORS:

Cytokines...

adiponectin, including various multimers from human blood; method
of

sepg. and assaying adiponectin multimer

Immunoassay...

enzyme-linked immunosorbent assay; method of sepg. and assaying
adiponectin multimer

Disease, animal...

metabolic syndrome X; method of sepg. and assaying adiponectin multimer

Disulfide group... Immunoassay... Human... Blood...

Albumins, reactions...

Kidney, disease... Liver, disease... Arteriosclerosis... Obesity... Gel permeation chromatography... Gel electrophoresis...

Digestion, chemical...

Sample preparation...

method of sepg. and assaying adiponectin multimer

Diabetes mellitus...

non-insulin-dependent; method of sepg. and assaying adiponectin multimer

Antibodies and Immunoglobulins...

to albumin, to adiponectin; method of sepg. and assaying

adiponectin

multimer

CAS REGISTRY NUMBERS:

9001-92-7 9003-05-8 9014-01-1 66676-43-5 209864-06-2 305344-27-8

method of sepg. and assaying adiponectin multimer

16/7/19 (Item 10 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

142407182 CA: 142(22)407182u PATENT

Method of pretreating sample and immunological assay method using the

same

INVENTOR(AUTHOR): Ebinuma, Hiroyuki; Yago, Hirokazu; Akimoto, Yuka; Miyazaki, Osamu; Kadowaki, Takashi; Yamauchi, Toshimasa

LOCATION: Japan,

ASSIGNEE: Daiichi Pure Chemicals Co., Ltd.; Toudai Tlo, Ltd.

PATENT: PCT International ; WO 200538458 A1 DATE: 20050428

APPLICATION: WO 2004JP15261 (20041015) *JP 2003354715 (20031015)

PAGES: 30 pp. CODEN: PIXXD2 LANGUAGE: Japanese

PATENT CLASSIFICATIONS:

CLASS: G01N-033/53A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;

BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;

GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;

LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;

PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;

UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ

; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;

BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU;
MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR;
NE; SN; TD; TG

SECTION:

CA209010 Biochemical Methods

IDENTIFIERS: adiponectin sample pretreatment immunoassay reductant
surfactant protease human blood

DESCRIPTORS:

Cytokines...

adiponectin, including various multimers; method of pretreating
sample

and immunol. assay method using the same

Mixtures...

adiponectin multimers; method of pretreating sample and immunol.
assay

method using the same

Immunoassay...

immunoblotting; method of pretreating sample and immunol. assay
method

using the same

Immunoassay... Sample preparation... Reducing agents... Acids,uses...

Surfactants... Salts,uses... Bacillus(bacterium genus)...

Streptomyces...

Aspergillus... Human... Blood...

method of pretreating sample and immunol. assay method using the
same

Antibodies and Immunoglobulins...

to adiponectin (mouse, human); method of pretreating sample and
immunol. assay method using the same

CAS REGISTRY NUMBERS:

305344-27-8 9001-92-7 3483-12-3 1185-53-1 7646-69-7 172520-74-0
9074-07-1 25155-30-0 769136-50-7 112-03-8 9002-93-1 9005-64-5

method of pretreating sample and immunol. assay method using the
same

64-19-7 151-21-3 uses, method of pretreating sample and immunol.
assay

method using the same

16/7/20 (Item 11 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

141223116 CA: 141(14)223116y JOURNAL

Canine adiponectin: Measurement of its blood concentration by ELISA
and

effects of obesity

AUTHOR(S): Omachi, Asako; Ishioka, Katsumi; Shibata, Haruki; Honjoh,
Tsutomu; Kimura, Kazuhiro; Saito, Masayuki

LOCATION: Lab. Biochem., Dep. Biomed. Sci., Grad. Sch. Veterinary
Med.,

Hokkaido Univ., Sapporo, Japan, 060-0818

JOURNAL: Jui Seikagaku (Jui Seikagaku) DATE: 2004 VOLUME: 41
NUMBER: 1

PAGES: 31-37 CODEN: JSUEBY ISSN: 1345-921X LANGUAGE: Japanese

PUBLISHER: Jui Seikagakkai

SECTION:

CA214008 Mammalian Pathological Biochemistry

IDENTIFIERS: blood adiponectin detn ELISA obesity dog

DESCRIPTORS:

Cytokines...

adiponectin; ELISA detn. of serum adiponectin and its effects on
canine

obesity

Blood serum... Obesity... Canis familiaris... Blood analysis...

ELISA detn. of serum adiponectin and its effects on canine obesity

Immunoassay...

enzyme-linked immunosorbent assay; ELISA detn. of serum
adiponectin and

its effects on canine obesity

CAS REGISTRY NUMBERS:

169494-85-3 ELISA detn. of serum adiponectin and its effects on
canine

obesity in relation to

16/7/21 (Item 12 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

141035612 CA: 141(3)35612h JOURNAL

Clinical significance of measuring adiponectin and development of
quantitation method

AUTHOR(S): Tanaka, Sachiyo; Kihara, Shinji; Funahashi, Toru

LOCATION: Graduate School of Medicine, Osaka University, Japan,

JOURNAL: Kensa to Gijutsu (Kensa to Gijutsu) DATE: 2003 VOLUME: 31

NUMBER: 8 PAGES: 763-766 CODEN: KTGIDU ISSN: 0301-2611 LANGUAGE:

Japanese PUBLISHER: Igaku Shoin Ltd.

SECTION:

CA209000 Biochemical Methods

CA214XXX Mammalian Pathological Biochemistry

IDENTIFIERS: review clin significance measurement adiponectin blood
level

, ELISA quantitation adiponectin blood level review

DESCRIPTORS:

Cytokines...

adiponectin; clin. significance of measuring adiponectin and
development of quantitation method

Blood analysis... Diabetes mellitus... Human... Kidney,disease...
Obesity

...

clin. significance of measuring adiponectin and development of
quantitation method

Immunoassay...

enzyme-linked immunosorbent assay; clin. significance of measuring adiponectin and development of quantitation method

16/7/22 (Item 13 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

140371257 CA: 140(23)371257q JOURNAL

Development of an ELISA kit for mouse and rat adiponectin

AUTHOR(S): Saitoh, Toshikazu; Akamatsu, Suguru; Tachikawa, Tetsuya; Muraguchi, Masahiro; Iwata, Fusako; Ohmoto, Yasukazu

LOCATION: Department of In Vitro Diagnostics, Otsuka Life Science Initiative, Otsuka Pharmaceutical Co., Ltd., Japan,

JOURNAL: Saibo (Saibo) DATE: 2003 VOLUME: 35 NUMBER: 7 PAGES: 274-277

CODEN: SAIBC7 ISSN: 1346-7557 LANGUAGE: Japanese PUBLISHER: Nyu Saiensusha

SECTION:

CA209010 Biochemical Methods

IDENTIFIERS: ELISA kit mouse rat adiponectin

DESCRIPTORS:

Cytokines...

adiponectin; development of ELISA kit for mouse and rat adiponectin

Test kits... Mus... Rat... Blood analysis...

development of ELISA kit for mouse and rat adiponectin

Immunoassay...

enzyme-linked immunosorbent assay; development of ELISA kit for mouse

and rat adiponectin

Antibodies and Immunoglobulins...

specific for mouse adiponectin, from rabbit serum; development of ELISA

kit for mouse and rat adiponectin

Animal cell line...

3T3-L1, culture supernatant of; development of ELISA kit for mouse and

rat adiponectin

16/7/23 (Item 14 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

140252318 CA: 140(16)252318a PATENT

Monoclonal antibody against adiponectin

INVENTOR(AUTHOR): Youn, Byung-soo; Yang, Young-soo; Lee, Nam-seok; Yu,

Kang-yeol; Youn, Moon-yeon; Park, Hong-je; Min, Sung-shik; Jeoung, Jae-jun

LOCATION: S. Korea
ASSIGNEE: Komed Co., Ltd.
PATENT: PCT International ; WO 200422596 A1 DATE: 20040318
APPLICATION: WO 2003KR1213 (20030619) *KR 53427 (20020905) *KR 38880
(20030616)
PAGES: 55 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-016/18A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD;
GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KZ; LC; LK; LR; LS; LT;
LU; LV;
MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU;
SC; SD;
SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU;
ZA; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM;
KE; LS
; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE;
ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR;
BF; BJ;
CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA215003 Immunochemistry
CA202XXX Mammalian Hormones
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: monoclonal antibody adiponectin
DESCRIPTORS:
Cytokines...
adiponectin; prepn. of monoclonal antibodies to
Diagnosis...
agents; monoclonal antibodies to human adiponectin for
Hybridoma...
B-cell, KCTC 10289BP; for antibodies to adiponectin
Diagnosis...
diabetes mellitus; monoclonal antibodies to human adiponectin for
Immunoassay...
enzyme-linked immunosorbent assay; monoclonal antibodies for
detection
of human adiponectin
Test kits...
for immunoassay of adiponectin
Antibodies and Immunoglobulins...
IgG1, monoclonal; to human adiponectin
Antibodies and Immunoglobulins...
immunoadhesins; of human adiponectin for prepn. of monoclonal
antibodies
Blood analysis...
monoclonal antibodies for detection of human adiponectin

Obesity...

monoclonal antibodies for detection of human adiponectin in
Human... Mus... Rat... Bos taurus... Equus caballus... Rabbit...
Capra...

Mammalia...

monoclonal antibodies to adiponectin of

Diabetes mellitus...

non-insulin-dependent; monoclonal antibodies for detection of
human

adiponectin in

Fusion proteins(chimeric proteins)...

of human adiponectin for prepn. of monoclonal antibodies

Diagnosis...

serodiagnosis; monoclonal antibodies to human adiponectin for

CAS REGISTRY NUMBERS:

670342-21-9 670342-22-0 unclaimed nucleotide sequence; monoclonal
antibody against adiponectin

670222-47-6 670222-48-7 670222-49-8 670222-50-1 670342-23-1
670342-25-3 unclaimed sequence; monoclonal antibody against
adiponectin

16/7/24 (Item 15 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

140140700 CA: 140(10)140700n PATENT

Novel polypeptides and polynucleotides obtained from human cDNA
libraries.

INVENTOR(AUTHOR): Rupp, Fabio; Wang, Jian-Rui; Zhou, Ping; Wehrman,
Tom;

Wang, Zhi Wei; Tang, Y. Tom

LOCATION: USA

ASSIGNEE: Nuvelo, Inc.

PATENT: PCT International ; WO 200407672 A2 DATE: 20040122

APPLICATION: WO 2003US21703 (20030709) *US PV395402 (20020712)

PAGES: 205 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
BY; BZ;

CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD;
GE; GH;

GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU;

LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT;
RO; RU;

SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ;
VC; VN;

YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH;
GM; KE

; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE;
DK;

EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK;
TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA203003 Biochemical Genetics
CA206XXX General Biochemistry
CA209XXX Biochemical Methods
CA213XXX Mammalian Biochemistry
CA263XXX Pharmaceuticals

IDENTIFIERS: protein cDNA sequence human

DESCRIPTORS:

Cytokines...

adiponectin, sequence homologs; novel polypeptides and
polynucleotides
obtained from human cDNA libraries.

Nucleic acid hybridization... Nucleic acid amplification(method)...

Reverse

transcription...
assay; novel polypeptides and polynucleotides obtained from human
cDNA
libraries.

Genetic mapping...

chromosomal; novel polypeptides and polynucleotides obtained from
human
cDNA libraries.

Animal tissue...

expression distribution in; novel polypeptides and polynucleotides
obtained from human cDNA libraries.

Animal cell line...

insect High Five, recombinant expression in; novel polypeptides
and
polynucleotides obtained from human cDNA libraries.

Antigens...

Ly-6, sequence homologs; novel polypeptides and polynucleotides
obtained from human cDNA libraries.

cDNA sequences... Protein sequences... Human... Molecular cloning...

Antibodies and Immunoglobulins... Probes(nucleic acid)...

Immunoassay...

DNA microarray technology... Protein microarray technology... Drug
screening...

novel polypeptides and polynucleotides obtained from human cDNA
libraries.

Escherichia coli...

recombinant expression in; novel polypeptides and polynucleotides
obtained from human cDNA libraries.

Carcinoembryonic antigen... Chemokines...

sequence homologs; novel polypeptides and polynucleotides
obtained from
human cDNA libraries.

CAS REGISTRY NUMBERS:

649581-71-5P 649581-73-7 649581-74-8 649581-76-0P 649581-78-2
649581-80-6P 649581-82-8 649581-84-0P 649581-86-2 649581-88-4P

649581-90-8 649581-92-0P 649581-94-2 649582-00-3P 649582-02-5
 649582-03-6 649582-04-7 649582-06-9P 649582-10-5P 649555-55-5
 649582-12-7 649582-16-1P 649555-57-7 649582-18-3 649582-20-7P
 649582-22-9 649582-23-0 649582-26-3P 649582-28-5 649582-31-0P
 532378-97-5 649582-33-2 649582-34-3 amino acid sequence; novel
 polypeptides and polynucleotides obtained from human cDNA
 libraries.
 649581-68-0 649581-69-1 649581-70-4 649581-72-6 649581-75-9
 649581-77-1 649581-79-3 649581-81-7 649581-83-9 649581-85-1
 649581-87-3 649581-89-5 649581-91-9 649581-93-1 649581-95-3
 649581-96-4 649581-97-5 649581-98-6 649581-99-7 649582-01-4
 649582-05-8 649582-07-0 649582-08-1 649582-09-2 649582-11-6
 649582-13-8 649582-14-9 649582-15-0 649582-17-2 649582-19-4
 649582-21-8 649582-24-1 649582-25-2 649582-27-4 649582-29-6
 649582-30-9 649582-32-1 nucleotide sequence; novel polypeptides
 and
 polynucleotides obtained from human cDNA libraries.
 649661-18-7 649661-20-1 649661-27-8 649661-30-3 649661-32-5
 649661-37-0 649661-38-1 649661-39-2 unclaimed nucleotide
 sequence;
 novel polypeptides and polynucleotides obtained from human cDNA
 libraries.
 649661-14-3 649661-15-4 649661-16-5 649661-17-6 649661-19-8
 649661-21-2 649661-22-3 649661-23-4 649661-24-5 649661-25-6
 649661-26-7 649555-56-6 649661-28-9 649661-29-0 649661-31-4
 649661-33-6 649661-34-7 649661-35-8 649661-36-9 unclaimed
 protein
 sequence; novel polypeptides and polynucleotides obtained from
 human
 cDNA libraries.

16/7/25 (Item 16 from file: 399)
 DIALOG(R)File 399:CA SEARCH(R)
 (c) 2009 American Chemical Society. All rts. reserv.

139031822 CA: 139(3)31822n PATENT
 Polynucleotides and their encoded polypeptides from human tissues
 INVENTOR(AUTHOR): Ghosh, Malabika; Tang, Y. Tom; Wang, Jian Rui;
 Wang,
 Zhiwei; Zhao, Qing A.; Xu, Chongjun; Mulero, Julio J.; Boyle, Bryan J.
 LOCATION: USA
 ASSIGNEE: Hyseq, Inc.
 PATENT: PCT International ; WO 200348326 A2 DATE: 20030612
 APPLICATION: WO 2002US38526 (20021202) *US 5499 (20011203)
 PAGES: 396 pp. CODEN: PIXXD2 LANGUAGE: English
 PATENT CLASSIFICATIONS:
 CLASS: C12N-000/A
 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
 BY; BZ;
 CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD;
 GE; GH;

GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU;
SD; SE;
SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM;
ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS;
MW; MZ
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES;
FI;
FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SI; SK; TR; BF; BJ; CF; CG;
CI; CM;
GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA203003 Biochemical Genetics
CA206XXX General Biochemistry
CA213XXX Mammalian Biochemistry

IDENTIFIERS: protein cDNA sequence human

DESCRIPTORS:

Cytokines...

adiponectin, homologs; polynucleotides and their encoded

polypeptides

from human tissues

Nucleic acid amplification(method)... Nucleic acid hybridization...

Reverse

transcription...

assay; polynucleotides and their encoded polypeptides from human
tissues

Genetic mapping...

chromosomal; polynucleotides and their encoded polypeptides from
human

tissues

Animal tissue...

expression profile in; polynucleotides and their encoded

polypeptides

from human tissues

Scavenger receptors...

homologs; polynucleotides and their encoded polypeptides from

human

tissues

Cell adhesion molecules...

IgCAM, homologs; polynucleotides and their encoded polypeptides

from

human tissues

Proteins...

lipocalin, neutrophil gelatinase-assocd., homologs;

polynucleotides and

their encoded polypeptides from human tissues

Cell proliferation... Nerve...

modifying proliferation of neural cells; polynucleotides and their
encoded polypeptides from human tissues

Proteins...

mucolipin 1, homologs; polynucleotides and their encoded
 polypeptides
 from human tissues
 Proteins...
 Nogo, homologs; polynucleotides and their encoded polypeptides
 from
 human tissues
 Proteins...
 peroxidase, homologs; polynucleotides and their encoded
 polypeptides
 from human tissues
 cDNA sequences... Protein sequences... Human... Molecular cloning...
 Antibodies... Probes(nucleic acid)... Primers(nucleic acid)...
 Immunoassay
 ... DNA microarray technology... Protein microarray technology...
 Proteins
 ...
 polynucleotides and their encoded polypeptides from human tissues
 Proteins...
 SAPAP (synaptic-assocd. protein 90/postsynaptic d. protein 95
 kDa-assocd. protein), homologs; polynucleotides and their encoded
 polypeptides from human tissues
 CAS REGISTRY NUMBERS:
 540847-66-3 540847-68-5 540745-49-1 540745-51-5 540745-53-7
 540745-55-9 540745-57-1 540745-59-3 540847-70-9 540847-72-1
 540847-73-2 540847-74-3 540847-78-7 540745-64-0 540847-80-1
 540847-81-2 540745-65-1 540745-66-2 540745-67-3 540745-68-4
 540745-69-5 540745-70-8 540745-71-9 540745-72-0 540745-73-1
 540745-74-2 540745-75-3 540745-76-4 540745-77-5 540745-78-6
 540745-79-7 540745-80-0 540745-81-1 540745-82-2 540745-83-3
 540745-84-4 540745-85-5 540745-86-6 540745-87-7 540745-88-8
 540745-89-9 540745-90-2 540745-91-3 540745-92-4 540745-93-5
 540745-94-6 540745-95-7 540745-96-8 540745-97-9 540745-98-0
 540745-99-1 540746-00-7 540746-01-8 540746-02-9 540746-03-0
 540746-04-1 540746-05-2 540746-06-3 540746-07-4 540746-08-5
 540746-09-6 540746-11-0 540746-12-1 540746-13-2 540746-14-3
 540746-15-4 540746-16-5 540746-17-6 540746-18-7 540746-19-8
 540746-20-1 540746-21-2 540746-22-3 540746-23-4 540746-24-5
 540746-25-6 540746-26-7 540746-27-8 540746-28-9 540746-29-0
 540746-30-3 540746-31-4 540746-32-5 540746-33-6 540746-34-7
 540746-35-8 540746-36-9 540746-37-0 540746-38-1 540746-39-2
 540746-40-5 540746-41-6 540746-42-7 540746-43-8 540746-44-9
 540746-45-0 540746-46-1 540746-47-2 540746-48-3 540746-49-4
 540746-50-7 540746-51-8 540746-52-9 540746-53-0 540746-54-1
 540746-55-2 540746-56-3 540746-57-4 540746-58-5 540746-59-6
 540746-60-9 540847-82-3 540847-83-4 540847-84-5 540746-61-0
 540746-62-1 540746-63-2 540746-64-3 540746-65-4 540746-66-5
 540746-67-6 540746-68-7 540746-69-8 540746-70-1 540746-71-2
 540746-72-3 540746-74-5 540746-75-6 540847-85-6 540746-76-7
 540746-78-9 540746-79-0 540746-80-3 540746-81-4 540746-82-5
 540746-83-6 540746-84-7 540746-85-8 540746-86-9 540847-86-7
 540847-90-3 540746-87-0 540847-92-5 540847-93-6 540746-88-1

540746-89-2	540746-90-5	540746-91-6	540746-92-7	540746-93-8
540746-94-9	540746-95-0	540746-96-1	540746-97-2	540746-98-3
540746-99-4	540747-00-0	540747-01-1	540747-02-2	540747-03-3
540747-04-4	540847-94-7	540847-98-1	540747-05-5	540848-00-8
540848-01-9	540747-06-6	540747-07-7	540747-08-8	540747-09-9
540747-10-2	540747-11-3	540747-12-4	540747-13-5	540747-14-6
540747-15-7	540747-16-8	540747-17-9	540747-18-0	540747-19-1
540747-20-4	540747-21-5	540747-22-6	540747-23-7	540747-24-8
540747-25-9	540747-26-0	540747-27-1	540747-28-2	540848-03-1
540848-05-3	540747-29-3	540747-30-6	540747-31-7	540747-32-8
540747-33-9	540747-34-0	540848-07-5	540848-09-7	540747-35-1
540747-36-2	540747-37-3	540747-38-4	540848-11-1	540848-13-3
540848-14-4	540848-17-7	540848-19-9	540747-39-5	540747-40-8
540747-41-9	540747-42-0	540747-43-1	540747-44-2	540747-45-3
540747-46-4	540747-47-5	540747-48-6	540747-49-7	540747-50-0
540747-51-1	540747-52-2	540848-20-2	540747-53-3	540747-54-4
540848-22-4	540747-55-5	540848-24-6	540848-28-0	540848-30-4
540747-56-6	540848-31-5	540848-34-8	540747-57-7	540848-36-0
540848-37-1	540747-58-8	540747-59-9	540747-60-2	540747-61-3
540747-62-4	540747-63-5	540747-64-6	540747-65-7	540747-66-8
540747-67-9	540747-68-0	540747-69-1	540747-70-4	540747-71-5
540848-38-2	540747-72-6	540747-73-7	540848-40-6	540848-42-8
540747-74-8	540747-75-9	540747-76-0	540848-46-2	540848-48-4
540747-77-1	540747-78-2	540747-79-3	540747-80-6	540848-49-5
540848-52-0	540747-81-7	540747-82-8	540747-83-9	540747-84-0
540747-85-1	540747-86-2	540747-88-4	540747-89-5	540747-90-8
540747-91-9	540747-92-0	540747-93-1	540747-94-2	540747-95-3
540848-54-2	540747-96-4	540848-55-3	540848-56-4	540848-60-0
540848-61-1	354525-58-9	354525-59-0	354525-60-3	354525-61-4
540747-97-5	540747-98-6	354525-64-7	354525-65-8	354525-66-9
354525-67-0	354525-68-1	354525-69-2	354525-71-6	540747-99-7
354525-73-8	354525-74-9	540748-00-3	540748-01-4	540748-03-6
540748-04-7	540748-05-8	540748-06-9	540748-07-0	540748-08-1
540748-09-2	540748-10-5	540748-11-6	540748-12-7	540748-13-8
540748-14-9	540748-15-0	540748-16-1	540748-17-2	540748-18-3
540848-62-2	540848-63-3	540848-64-4	540748-19-4	540848-67-7
540748-20-7	540848-69-9	540848-70-2	540848-71-3	540848-72-4
540848-73-5	540848-74-6	540848-75-7	540848-76-8	540848-77-9
540848-78-0	540748-21-8	540848-79-1	540848-82-6	540748-22-9
540848-84-8	540848-85-9	540848-86-0	540748-23-0	540848-87-1
540848-90-6	540848-91-7	540848-92-8	540848-93-9	540848-94-0
540848-95-1	540848-96-2	540848-97-3	540849-00-1	540849-02-3
540849-03-4	540849-04-5	540849-05-6	540849-06-7	540849-07-8
540849-08-9	540748-24-1	540849-09-0	540849-11-4	540849-13-6
540748-25-2	540849-14-7	540849-16-9	540849-18-1	540748-26-3
540748-27-4	540849-19-2	540849-21-6	540849-23-8	540849-24-9
540748-28-5	540748-29-6	540748-30-9	540748-31-0	540748-32-1
540849-25-0	540849-26-1	540849-29-4	540748-33-2	540849-31-8
540748-34-3	540849-34-1	540849-36-3	540748-35-4	540748-36-5
540849-37-4	540849-38-5	540849-40-9	540849-42-1	540849-43-2
540849-44-3	540849-45-4	540849-46-5	540849-47-6	540748-37-6
540748-38-7	540748-39-8	540748-40-1	540748-41-2	540849-49-8

540748-42-3 540849-51-2 540849-53-4 540849-55-6 540849-57-8
 540849-59-0 540849-60-3 540849-62-5 540849-64-7 540849-66-9
 540849-68-1 540849-70-5 540849-72-7 540849-74-9 540849-76-1
 540849-77-2 540748-43-4 540748-44-5 540748-45-6 540748-46-7
 540748-47-8 540748-48-9 148916-02-3 540748-49-0 540748-50-3
 540748-51-4 540748-52-5 540748-53-6 540748-54-7 540748-55-8
 540748-56-9 540748-57-0 540748-58-1 amino acid sequence;
 polynucleotides and their encoded polypeptides from human tissues
 96282-35-8 9002-72-6 homologs; polynucleotides and their encoded
 polypeptides from human tissues
 540847-62-9 540847-63-0 540847-64-1 540847-65-2 540847-67-4
 540847-69-6 540847-71-0 540847-75-4 540847-76-5 540847-77-6
 540847-79-8 540847-87-8 540847-88-9 540847-89-0 540847-91-4
 540847-95-8 540847-96-9 540847-97-0 540847-99-2 540848-02-0
 540848-04-2 540848-06-4 540848-08-6 540848-10-0 540848-12-2
 540848-15-5 540848-16-6 540848-18-8 540848-21-3 540848-23-5
 540848-25-7 540848-26-8 540848-27-9 540848-29-1 540848-32-6
 540848-33-7 540848-35-9 540848-39-3 540848-41-7 540848-43-9
 540848-44-0 540848-45-1 540848-47-3 540848-50-8 540848-51-9
 540848-53-1 540848-57-5 540848-58-6 540848-59-7 540848-65-5
 540848-66-6 540848-68-8 540848-80-4 540848-81-5 540848-83-7
 540848-88-2 540848-89-3 540848-98-4 540848-99-5 540849-01-2
 540849-10-3 540849-12-5 540849-15-8 540849-17-0 540849-20-5
 540849-22-7 540849-27-2 540849-28-3 540849-30-7 540849-32-9
 540849-33-0 540849-35-2 540849-39-6 540849-41-0 540849-48-7
 540849-50-1 540849-52-3 540849-54-5 540849-56-7 540849-58-9
 540849-61-4 540849-63-6 540849-65-8 540849-67-0 540849-69-2
 540849-71-6 540849-73-8 540849-75-0 nucleotide sequence;
 polynucleotides and their encoded polypeptides from human tissues
 540889-79-0 540889-80-3 540889-81-4 540889-82-5 540889-83-6
 540889-84-7 540889-85-8 540889-86-9 540889-87-0 540889-88-1
 540889-89-2 unclaimed protein sequence; polynucleotides and their
 encoded polypeptides from human tissues

16/7/26 (Item 17 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

138201087 CA: 138(14)201087a JOURNAL

Adiponectin ELISA

AUTHOR(S): Omoto, Yasukazu; Uehara, Shigeru; Sumida, Takumi

LOCATION: Biological Research Institute, Otsuka Pharmaceutical Co.,
 Ltd.,
 Japan,

JOURNAL: BIO Clin. (BIO Clinica) DATE: 2002 VOLUME: 17 NUMBER: 2

PAGES: 156-159 CODEN: BCILCY ISSN: 0919-8237 LANGUAGE: Japanese

PUBLISHER: Hokuryukan

SECTION:

CA209000 Biochemical Methods

CA215XXX Immunochemistry

IDENTIFIERS: review adiponectin ELISA disease diagnosis

DESCRIPTORS:

Diagnosis...

adiponectin ELISA and disease diagnosis

Cytokines...

adiponectin; adiponectin ELISA and disease diagnosis

Immunoassay...

enzyme-linked immunosorbent assay; adiponectin ELISA and disease diagnosis

16/7/27 (Item 18 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

138183509 CA: 138(13)183509h PATENT

Method for diagnosing or monitoring carbohydrate metabolism abnormality

INVENTOR(AUTHOR): Tomita, Motowo; Nakano, Yasuko; Hirose, Hiroshi; Matsubara, Koichi

LOCATION: Japan,

ASSIGNEE: Rebio Gen, Inc.; Keio University

PATENT: PCT International; WO 200316906 A1 DATE: 20030227

APPLICATION: WO 2002JP8331 (20020816) *JP 2001248047 (20010817)

PAGES: 37 pp. CODEN: PIXXD2 LANGUAGE: Japanese

PATENT CLASSIFICATIONS:

CLASS: G01N-033/53A; G01N-033/577B; C07K-016/18B; C12P-021/08B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR;

BY; BZ;

CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD;

GE; GH;

GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;

LT; LU;

LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU;

SD; SE;

SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU;

ZA; ZM;

ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM;

KE; LS

; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE;

ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF;

CG; CI;

CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA209010 Biochemical Methods

CA214XXX Mammalian Pathological Biochemistry

IDENTIFIERS: carbohydrate metab abnormality diabetes diagnosis

adiponectin immunoassay

DESCRIPTORS:

Cytokines...

adiponectin, human; natural type; method for diagnosing or monitoring

carbohydrate metab. abnormality
 Immunoassay...
 enzyme-linked immunosorbent assay; method for diagnosing or
 monitoring
 carbohydrate metab. abnormality
 Hybridoma...
 FERM BP-7660; method for diagnosing or monitoring carbohydrate
 metab.
 abnormality
 Hybridoma...
 FERM BP-7661; method for diagnosing or monitoring carbohydrate
 metab.
 abnormality
 Carbohydrates, biological studies...
 metab., abnormality; method for diagnosing or monitoring
 carbohydrate
 metab. abnormality
 Diagnosis... Test kits... Human...
 method for diagnosing or monitoring carbohydrate metab.
 abnormality
 Antibodies...
 monoclonal; method for diagnosing or monitoring carbohydrate
 metab.
 abnormality
 Diabetes mellitus...
 non-insulin-dependent; method for diagnosing or monitoring
 carbohydrate
 metab. abnormality
 CAS REGISTRY NUMBERS:
 9004-10-8 biological studies, resistance; method for diagnosing or
 monitoring carbohydrate metab. abnormality
 504-78-9D deriv., method for diagnosing or monitoring carbohydrate
 metab.
 abnormality
 111025-46-8 method for diagnosing or monitoring carbohydrate metab.
 abnormality
 ? ds

Set	Items	Description
S1	475	SERUM (3N) SAMPLE (3N) (TREATMENT OR PRETREATMENT)
S2	146	RD S1 (unique items)
S3	117	S2 NOT PY>2006
S4	117	RD S3 (unique items)
S5	3720408	4 AND ACID
S6	24	S4 AND ACID
S7	3	S6 AND (IMMUNOASSAY OR ANTIBODY)
S8	55814	ADIPONECTIN
S9	3402	S8 AND (ASSAY OR IMMUNOASSY)
S10	1185	S9 NOT PY>2006
S11	352	RD S10 (unique items)
S12	0	ADIPONECTIN 5N IMMUNOASSAY
S13	0	ADIPONECTIN 10N IMMUNOASSAY

S14	510	ADIPONECTIN AND IMMUNOASSAY
S15	27	S11 AND S14
S16	27	RD S15 (unique items)
?		

---Logging off of Dialog---

? logoff

```

18nov09 17:11:13 User226352 Session D1191.3
  $11.36    1.835 DialUnits File5
    $56.12  23 Type(s) in Format  7
    $56.12  23 Types
$67.48 Estimated cost File5
    $0.84    0.112 DialUnits File6
$0.84 Estimated cost File6
    $3.20    0.496 DialUnits File24
$3.20 Estimated cost File24
    $51.08    1.794 DialUnits File34
    $16.56    2 Type(s) in Format  7
    $16.56    2 Types
$67.64 Estimated cost File34
    $0.60    0.080 DialUnits File40
$0.60 Estimated cost File40
    $0.71    0.109 DialUnits File41
$0.71 Estimated cost File41
    $2.43    0.469 DialUnits File45
$2.43 Estimated cost File45
    $3.04    0.639 DialUnits File50
$3.04 Estimated cost File50
    $1.37    0.321 DialUnits File65
$1.37 Estimated cost File65
    $7.69    0.707 DialUnits File71
    $2.60    1 Type(s) in Format  7
    $2.60    1 Types
$10.29 Estimated cost File71
    $22.32    1.611 DialUnits File72
    $7.66    2 Type(s) in Format  7
    $7.66    2 Types
$29.98 Estimated cost File72
    $22.62    1.633 DialUnits File73
$22.62 Estimated cost File73
    $1.93    0.299 DialUnits File76
$1.93 Estimated cost File76
    $0.69    0.156 DialUnits File98
$0.69 Estimated cost File98
    $1.99    0.306 DialUnits File103
$1.99 Estimated cost File103
    $0.58    0.090 DialUnits File136
$0.58 Estimated cost File136
    $0.34    0.109 DialUnits File143
$0.34 Estimated cost File143

```

```

$5.81      1.137 DialUnits File144
$5.81 Estimated cost File144
$4.73      1.344 DialUnits File154
$0.48      2 Type(s) in Format 7
$0.48      2 Types
$5.21 Estimated cost File154
$5.01      1.424 DialUnits File155
$5.01 Estimated cost File155
$2.45      0.399 DialUnits File156
$2.45 Estimated cost File156
$1.59      0.340 DialUnits File162
$1.59 Estimated cost File162
$2.15      0.156 DialUnits File172
$2.15 Estimated cost File172
$2.92      0.202 DialUnits File305
$5.82      1 Type(s) in Format 7
$5.82      1 Types
$8.74 Estimated cost File305
$0.19      0.051 DialUnits File369
$0.19 Estimated cost File369
$0.13      0.036 DialUnits File370
$0.13 Estimated cost File370
$0.56      0.194 DialUnits File393
$0.56 Estimated cost File393
$24.84     1.901 DialUnits File399
$56.62     19 Type(s) in Format 7
$56.62     19 Types
$81.46 Estimated cost File399
$3.11      0.109 DialUnits File434
$3.11 Estimated cost File434
OneSearch, 29 files, 18.060 DialUnits FileOS
$4.80 TELNET
$336.94 Estimated cost this search
$336.94 Estimated total session cost 18.444 DialUnits
Logoff: level 05.27.00 D 17:11:13

```